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Swelling-activated Cl− current (ICl,swell) is an outwardly-rectifying current that 
plays an important role in cardiac electrical activity, cellular volume regulation, 
apoptosis, and acts as a potential effector of mechanoelectrical feedback.  Persistent 
activation of ICl,swell has been observed in a number of models of cardiovascular disease.  
Previously we showed that angiotensin II (Ang II), endothelin-1 (ET-1), endothelial 
growth factor receptor (EGFR), and reactive oxygen species (ROS) produced by NADPH 
oxidase (NOX) and mitochondria are involved in the activation of ICl,swell by both osmotic 
swelling and β1 integrin stretch.  Sphingolipid metabolism is modulated in several 
 xiii 
 
cardiopathologies and because sphingolipids are bioactive lipids involved in signaling 
cascades that overlap significantly with these modulators of ICl,swell, we investigated the 
role of sphingolipids in the regulation of ICl,swell in cardiac ventricular myocytes.   
Under isoosmotic conditions that isolate anions currents, addition of exogenous, 
cell permeant C2-ceramide (C2-Cer) elicited an outwardly-rectifying Cl− current that 
reversed near the Cl− equilibrium potential (ECl) in both physiological and symmetrical 
Cl− gradients. This current was inhibited by the ICl,swell-specific blockers DCPIB.  
Dihydro-C2-ceramide (C2-H2Cer), the inactive analogue of C2-Cer, failed to elicit current.  
These data strongly suggest that the identity of C2-Cer-induced Cl− current is ICl,swell and  
indicate that sphingolipid signaling pathways may be involved. 
Bacterial sphingomyelinase (SMase), which converts endogenous sphingomyelin 
in the outer leaflet of the sarcolemmal membrane to native chain-length ceramides, 
elicited a DCPIB-sensitive Cl− current.  SMase-induced current is also suppressed by 
tamoxifen, which under conditions that isolate anion currents is a specific inhibitor of 
ICl,swell.  SMase-induced ICl,swell was abrogated by ebselen, a membrane permeant 
glutathione peroxidase mimetic that dismutates H2O2 to H2O.  This suggests that ROS are 
required mediators of SMase-induced activation of ICl,swell.  Both NOX and mitochondria 
are important sources of ROS in cardiomyocytes and both have been implicated in 
modulating ICl,swell.  Blocking NOX with apocynin or the NOX fusion peptide inhibitor 
gp91ds-tat had no effect on SMase-induced current.  However, pretreatment of 
cardiomyocytes with gp91ds-tat reduced the maximum current amplitude of SMase-
induced ICl,swell, indicating that NOX may play a time-dependent role in this mechanism. 
 xiv 
 
By contrast, the mitochondrial Complex I blocker rotenone, which suppresses extra-
mitochondrial ROS release by Complex III, completely suppresses SMase-induced 
ICl,swell.  Additionally, SMase-induced ICl,swell is partially inhibited by blockade of 
mitochondrial KATP (mitoKATP) channels with 5-hydroxy-decanoic acid (5-HD).  
MitoKATP channels have been implicated as modulators of mitochondrial ROS release. 
Thus these data suggest that mitochondrial ROS generation is required for SMase-
induced activation of ICl,swell.   
Ceramides are metabolized to form several sphingolipids, including sphingosine-
1-phosphate (S1P). We tested whether ceramide metabolites are responsible for eliciting 
ICl,swell. Under isosmotic conditions that isolate anion currents, SMase-induced ICl,swell was 
abrogated by blockade of ceramidase, which converts ceramide to sphingosine, with D-
erythro-MAPP.  SMase-induced ICl,swell also was suppressed by inhibition of sphingosine 
kinase with DL-threo-dihydrosphingosine. These data suggested that the ceramide 
metabolite S1P is likely to stimulate ICl,swell. As expected, exogenous S1P elicited an 
outwardly rectifying Cl−  current that was fully inhibited by DCPIB. As seen with SMase-
induced ICl,swell, S1P-induced ICl,swell was fully inhibited by rotenone. In contrast to results 
with SMase, S1P-induced current was partially inhibited by blockade of NOX with 
apocynin. These data indicate that S1P is a necessary component of SMase-induced 
ICl,swell activation and that the action of exogenous S1P involves ROS from both 
mitochondria and NOX.  Importantly, the fact that exogenous C2-ceramide also activates 
ICl,swell even though C2-ceramide may not metabolized to S1P in native cells. Thus, it 
 xv 
 
seems likely that ceramides can elicit ICl,swell via S1P and also by a distinct pathway and 
that both pathways converge at mitochondrial ROS. 
In order to determine the role of ERK in the proposed signaling pathway that 
regulates ICl,swell, we examined the effect of ERK inhibitors PD98059 and U0126 on the 
activation of ICl,swell.  Both of these agents partially inhibited SMase-induced activation of 
ICl,swell, indicating SMase acts through both ERK-dependent and ERK-independent 
signaling pathways. 
HL-1 cells are derived from a murine atrial cell line that retains phenotypic 
characteristics of adult cardiomyocytes.  Recently, ICl,swell has been observed in HL-1 
cells with similar regulatory mechanisms to those seen in native cells.  We showed that 
SMase elicits an outwardly-rectifying, DCPIB-sensitive Cl−  current that reverses near ECl 
in HL-1 cells.  Finally, we confirmed the production of ROS by SMase-induced signaling 
by flow cytometry in HL-1 cells using the nominally H2O2-selective fluorescent probe C-
H2DCFDA-AM.  Exposure to SMase increased ROS production, as did the positive 
control H2O2.  SMase-induced ROS generation was suppressed by pretreatment with 
rotenone but was unaffected by pretreatment with gp91ds-tat.   
These data indicate that exogenous and endogenous sphingolipids elicit ICl,swell in 
cardiomyocytes by stimulating mitochondrial ROS production.  NOX may contribute to 
the ROS generation, but is not a required step in this mechanism.  Sphingolipid signaling 
is likely to play an important role in stimulating ROS production and activating ICl,swell in 
a number of cardiovascular diseases. 
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Chapter 1        
INTRODUCTION 
 
 
The volume-sensitive Cl− current, ICl,swell, is elicited in cardiac myocytes by 
osmotic swelling, hydrostatic inflation, β1 integrin stretch, and in several models of 
cardiac disease.  In turn, ICl,swell modulates cardiac electrical activity, cell volume, 
apoptosis, and is implicated in ischemic preconditioning (Baumgarten et al., 2005; Duan 
et al., 2005; Hume et al., 2000).  Regulation of ICl,swell is complex and involves a number 
of signaling pathways.  Recently, reactive oxygen species (ROS) were identified as a 
downstream effector, and exogenous H2O2 elicits ICl,swell in cardiomyocytes (Browe and 
Baumgarten, 2004; Browe and Baumgarten, 2006; Ren et al., 2008) and other cells 
(Haskew-Layton et al., 2005; Shimizu et al., 2004; Varela et al., 2004).   
Many of the signaling cascades that activate ICl,swell overlap those involved in 
sphingolipid signaling (Hannun and Obeid, 2008; Levade et al., 2001; Spiegel et al., 
2002), raising the possibility that certain sphingolipids might regulate ICl,swell.  Initially 
sphingolipids were considered to be structural components of membranes without further 
function.  More recently, sphingolipids, specifically ceramide and sphingosine, were 
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recognized as bioactive molecules that participate in a number of signaling cascades and 
mediate apoptosis, mitogenesis, and other cellular processes.  Alterations in sphingolipid 
metabolism are implicated in cardiovascular diseases, including congestive heart failure, 
atherosclerosis, and ischemia/reperfusion injury (Chatterjee et al., 2006; Levade et al., 
2001).  Sphingosine kinase, which phosphorylates the ceramide metabolite sphingosine, 
mediates Ang II-induced PI-3K activation (Mulders et al., 2006) and EGFR up-regulation 
(Tanimoto et al., 2004b) in vascular smooth muscle cells.  Exogenous ceramide elicits 
ROS production via NADPH oxidase in bovine coronary artery cells (Zhang et al., 2003) 
and the via mitochondrial electron transport chain in rat liver (Garcia-Ruiz et al., 1997b) 
and heart (Gudz et al., 1997).  Moreover, ICl,swell has been postulated to control the 
ceramide-induced apoptotic volume decrease in cardiomyocytes (d'Anglemont de 
Tassigny et al., 2004), but effects of ceramide on ICl,swell were not assessed.  We 
hypothesize that sphingolipids will activate ICl,swell through one or more of these shared 
signaling pathways.  ROS generation in particular is a prime candidate for this activation. 
1.1.  Sphingolipid biosynthesis and metabolism  
Sphingolipids are important components of all eukaryotic cells and are found in 
the plasma membrane, lysosomes, and Golgi and mitochondrial membranes (Hannun, 
1994; Hannun and Obeid, 2008).  They are usually classified into two separate groups: 
sphingophospholipids, which include sphingomyelin, ceramide, sphingosine and the 
phosphorylated forms of these lipids; and glycosphingolipids, which include gangliosides 
and others that accumulate in lipid storage diseases such as Neimann-Pick disease. 
The sphingoid backbone confers a more asymmetric structure than the 
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diacylglycerol moiety of phosphatidylcholine (Kolesnick, 2002).  The interface region of 
phosphatidylcholine contains a glycerol backbone and fatty ester linkages.  By contrast, 
the interface region of sphingolipids contains an amide-linked fatty acid, a free hydroxyl 
group at the third position, and a trans double bond between carbons four and five (Auge 
et al., 2000) (see Figure 1).  These differences make the interface region of sphingolipids 
more polar than their phosphatidylcholine counterparts and, thus, allows for more 
opportunities for hydrogen bonding and greater interaction with polar solvents, features 
that may contribute to the unusually potent bioactivity of sphingolipids.  In addition, the 
sphingoid backbone distinguishes sphingolipids from other amphipathic lipids.   
 A number of enzymes are involved in sphingolipid biosynthesis and metabolism.  
Ceramide, which forms the backbone of all sphingolipids, is synthesized de novo 
beginning with the condensation of serine and palmitoyl-CoA to form 3-ketosphinganine 
by   serine  palmitoyltransferase  at  the  cytosolic  face   of   the   endoplasmic  reticulum. 
Reduction of 3-ketosphinganine leads to formation of sphinganine, which is N-acylated 
with free fatty acids by ceramide synthase to form dihydroceramide.  This step is where 
ceramide acyl chain length of sphingolipid sub-species is established.  The bond between 
carbons four and five of dihydroceramide is then desaturated to form ceramide.  
Ceramide is subsequently transported to Golgi either via vesicular [coat protein complex 
II (COP II)-dependent] or and non-vesicular [ceramide transfer protein (CERT)- 
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Figure 1: Schematic of sphingolipid synthesis and metabolism (Auge et al., 1996).  
Ceramide forms the backbone of all sphingolipids.  A majority of ceramide in cells is 
produced from the action of sphingomyelinases that cleave the phosphocholine group 
from sphingomyelin.  Additionally, ceramide can be synthesized de novo from palmitoyl-
CoA, serine, and fatty acids.  Ceramide can then be further enzymatically modified by 
phosphorylation or glycosylation.  Ceramide may also be metabolized by ceramidases to 
sphingosine which in turn is phosphorylated by sphingosine kinases to form the bioactive 
metabolite sphingosine-1-phosphate. 
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dependent] transport mechanisms (Perry and Ridgway, 2005).  Once in the Golgi, 
ceramide is further processed to form other sphingolipids. 
 While de novo synthesis is an important source of ceramide in cells, much of the  
ceramide present under physiological and several pathological conditions is generated by 
the catabolism of sphingomyelin and other sphingolipids (Kitatani et al., 2008). 
Hydrolysis of sphingomyelin by enzymes known as sphingomyelin phosphodiesterases or 
simply sphingomyelinases, yields ceramide and phosphocholine.  Additionally, ceramide 
is produced through a salvage pathway that begins within acidic cellular compartments 
including late endosomes and lysosomes (Kitatani et al., 2008).  Sphingomyelinases are 
stimulated by TNF-α (Kim et al., 1991), Fas ligand (Brenner et al., 1998), and oxidative 
stress (Goldkorn et al., 1998) and the different members of this enzyme family are 
classified by their pH optima and their cation dependence.  Acid sphingomyelinase (A-
SMase) is primarily present in lysosomes and has a maximum activity over a pH range of 
3.5 – 5.2 (Hannun, 1996; Hannun and Obeid, 2008).  There is evidence of a secreted 
isotype of acid sphingomyelinase (known as secretory sphingomyelinase, or S-SMase) 
that is Zn2+–dependent and has been implicated in atherosclerotic development.  Neutral 
sphingomyelinases (N-SMases) are Mg2+− or Mn2+–dependent transmembrane enzymes 
with optimal activity near pH 7.5 (Chatterjee, 1999).  Aside from the plasma membrane, 
N-SMases, along with alkaline sphingomyelinase, have been localized to mitochondria, 
nuclear membranes, and the endoplasmic reticulum (Merrill, Jr. et al., 1997; Hannun and 
Obeid, 2008).  
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Ceramide may be further metabolized by ceramidases to form sphingosine.  This 
is important in the ceramide salvage pathway, where acid ceramidase hydrolyzes the 
ceramide fatty acids, allowing the resulting sphingosine to leave the lysosome (Kitatani et 
al., 2008).  Sphingosine may then be phosphorylated by sphingosine kinases to form the 
potent signaling lipid, sphingosine-1-phosphate (S1P).  There are two primary isotypes of 
sphingosine kinase, denoted as SPHK1 and SPHK2 (Spiegel and Milstien, 2002).  
Although there is significant sequence homology between the two isotypes, they exhibit 
significantly different properties and distributions.  SPHK1 is smaller and is expressed 
primarily in the cytosol, and the isoforms exhibit significant differences in their kinetics 
and temporal expression during development (Spiegel and Milstien, 2002).  Thus S1P 
generation and its subsequent signaling effects may show significant cell-type, temporal, 
and compartmental specificity. 
1.2  Sphingolipids in cardiovascular physiology and pathology 
Ceramide accumulation is seen in many forms of human cardiovascular disease, 
including congestive heart failure (CHF), acute myocardial infarction, diabetic 
cardiomyopathy, atherosclerosis, and ischemia/reperfusion injury (Auge et al., 2000; 
Chatterjee et al., 2006), and S1P plays a role in cardioprotection, cardiac hypertrophy, 
and normal cardiac physiology (Karliner, 2009; Means and Brown, 2009).  While the role 
of sphingolipids has been extensively studied, there is still much that is unknown about 
their underlying physiological and pathophysiological mechanisms. 
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Sphingolipids have been implicated as mediators of atherogenesis.  Sphingomye-
lin is a component of low-density lipoprotein (LDL) and may enter cells via the LDL 
receptor pathway.  Sphingomyelin accumulates in human atheromas and plasma levels 
are elevated in patients with coronary artery disease (Jiang et al., 2000).  The relative 
concentration of sphingomyelin relative to other phospholipids is important for 
determining the level of lipoprotein sphingomyelin hydrolysis and risk of foam cell 
development.  S-SMase, an acid sphingomyelinase found in secretory vesicles near the 
plasma membrane, has been implicated in the aggregation of LDL on endothelial cells 
during fatty streak formation (Marathe et al., 1998).  S-SMase is also upregulated in 
patients with chronic heart failure (Doehner et al., 2007).  S1P circulates in plasma 
primarily as a component of high density lipoprotein (HDL), and the ability of S1P to 
inhibit endothelial cell apoptosis has led some to suggest that this is at least part of the 
origin of the cardioprotective effects of HDL (Chatterjee et al., 2006; Murata et al., 
2000).  Other studies indicate, however, that S1P has pro-atherogenic properties (Xu et 
al., 2004; Chatterjee et al., 2006),    
Sphingolipid metabolism and signaling also may be important in ischemia/reper-
fusion injury.  A-SMase activity is induced during transient focal cerebral ischemia, and 
pharmacological inhibition of A-SMase and knockout of A-SMase in mice are protective 
against ischemic injury (Yu et al., 2000).  During myocardial infarction, platelets likely 
release S1P during myocardial infarction (Ford, 2002).  Both exogenous S1P and GM-1 
ganglioside-induced production of intracellular S1P improve cardiac function as 
measured by left ventricular diastolic pressure or creatine kinase release following global 
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ischemia/reperfusion (Vessey et al., 2008; Jin et al., 2002).  The use of specific S1P 
receptor sub-type 1 (S1P1) agonist antibodies provides the same level of cardioprotection 
as exogenous S1P (Zhang et al., 2007b).  There is also evidence for S1P2 and S1P3 
receptor-mediated cardioprotection, as S1P2, S1P3, and S1P2,3 double knockout mice 
demonstrate a significant increase in infarct size following ischemia (Means et al., 2007).   
Additionally, sphingolipids may affect cardiovascular biology through their 
modulation of cardiac ion channels.  Sphingolipids are known to have effects on a 
number of channel types, including K+, Ca2+, and anion channels.  These 
electrophysiological effects are discussed further in the next section. 
1.3 The effect of sphingolipids on cardiac electrical activity and ion channels 
Sphingolipids are involved in the regulation of a number of K+ channels found in 
heart (Ramu et al., 2006; Chapman et al., 2005; Bai et al., 2007) and other tissues (Zhang 
et al., 2002; Wu et al., 2001; Hida et al., 1998; Gulbins et al., 1997; Chik et al., 2001; 
Bock et al., 2003).  Exogenous C2-ceramide and endogenous ceramides that are generated 
by SMase elicit a time-dependent inhibition of hERG K+ channel function that is 
precluded by treatment with the superoxide dismutase (SOD) mimetic, Mn(III) tetra(4-
benzoic acid) porphyrin chloride (MnTBAP) (Bai et al., 2007).  Ceramide also induces 
hERG downregulation and increases lysosomal degradation of activated inwardly 
rectifying K+ channels that give rise to IK,ACh and contribute to resting membrane 
potential in cardiomyocytes of a number of species (Means and Brown, 2009).  This 
response is attributed to S1P3 receptor activation because suramin, a putative S1P3 
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antagonist, attenuates the effect on IK,ACh (Ancellin and Hla, 1999).  The S1P3 receptor 
may play a role in heart rate regulation, evidenced by the observation that S1P3 
stimulation induces bradycardia in mice and humans (Sanna et al., 2004; Budde et al., 
2002).  Outward K+ current attributable to Ca+-activated K+ channels is also inhibited by 
ceramide in rat pinealocytes (Chik et al., 2001).  One possible mechanism for such 
inhibition is the formation of lipid rafts.  Outwardly rectifying n-type K+ channels are 
inhibited due to clustering of the channels in C16-ceramide enriched membrane rafts 
(Bock et al., 2003).  The importance of lipid rafts, which have higher cholesterol and 
sphingolipid content relative to other membrane domains, in the regulation of the 
pacemaker current (If) has also been suggested (Barbuti et al., 2004). 
Additional evidence suggests a role for sphingolipids in regulating Ca2+ channels. 
Stimulation of CD95 receptor blocks Ca2+ influx in lymphocytes through store-operated 
calcium channels (CRAC) that is dependent on ceramide generation from A-SMase 
(Lepple-Wienhues et al., 1999).  Reversible CRAC inhibition by exogenous ceramides, 
but not their inactive analogues, is also observed in lymphocytes.  By contrast, there are 
reports that ceramide increases CRAC current.  In Jurkat human T cells, exogenous 
ceramide increases intracellular calcium through a thapsigargin-sensitive mechanism 
(Colina et al., 2005b), although there is some evidence to suggest that this is due to the 
phosphorylation of ceramide to form ceramide-1-phosphate (C1P) rather than a direct 
effect of ceramide (Colina et al., 2005a).   
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Sphingolipids have been implicated in the regulation of Cl− channels in skeletal 
muscle (De Luca et al., 1998), airway epithelium (Ito et al., 2004), cardiac muscle 
(d'Anglemont de Tassigny et al., 2004), and Xenopus laevis oocytes (Souktani et al., 
2000).  Exogenous, short-chain C2-ceramide prevents the PKC-induced decrease in fast 
twitch skeletal muscle Cl− conductance due to the phorbol ester, 4-β-phorbol-12,12-
dibutyrate (4-β-PDB) .  The mechanism of C2-ceramide in this system is thought to be 
through an okadaic acid-sensitive serine-threonine phosphatase that counteracts PKC 
activity (De Luca et al., 1998).  N,N-dimethyl-D-erythro-sphingosine (DMS), a 
sphinigosine kinase inhibitor, also activates a PKC-sensitive, ICl,swell-like Cl− current in 
Xenopus oocytes that is blocked by phosphatase inhibitor phorbol myristate acetate 
(PMA) (Souktani et al., 2000).  By contrast, PMA had no effect on bacterial SMase-
induced inhibition of CFTR  Cl− current (Ito et al., 2004).  The ceramidase inhibitor N-
oleoylethanolamine and the glucosylceramide synthase inhibitor 1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (PDMP) both potentiate SMase-induced CFTR 
inhibition, indicating ceramide, and not its metabolites, are responsible for the effect.  Ito 
et al. (2004) have suggested that ceramide may interact specifically with the open state of 
CFTR channels, similar to their interaction with sulfonylureas.  This mechanism remains 
unexplored, however.   
1.4 Sphingolipid-induced signaling 
Sphingolipid signaling has been well-studied over the past couple of decades. 
Although much is known about which signaling cascades are modulated by 
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sphingolipids, the pathways involved are complex, and there is still much that is not 
understood about how these different signaling pathways interact.  For example, it has 
been well documented that the bioactive sphingolipids ceramide and S1P typically 
display antagonistic effects on cellular processes such as apoptosis.  Such data support 
the concept that signaling is controlled by a ceramide-S1P rheostat, where the relative 
concentrations of these two signaling molecules determines the dominant signaling 
pathway.  Recent evidence points, however, to the possibility that ceramide and S1P may 
have similar effects in some instances.  For example, both ceramide and S1P induced 
ROS generation in bovine coronary arteries (Zhang et al., 2003; Keller et al., 2006).  The 
following sections outline the major sphingolipid-induced signaling cascades and their 
regulatory pathways. 
1.4.1 PKC/protein phosphatase signaling cascades 
Protein kinase C (PKC) is a family of enzymes that regulate protein function by 
phosphorylating hydroxyl groups of serine/threonine residues.  Protein phosphatases 
antagonize this process be dephosphorylating the serine/threonine residue.  Ceramide 
stimulates a group of serine/threonine phosphatases know as ceramide-activated protein 
phosphatases (CAPPs), which includes PP1 and PP2A (Dobrowsky and Hannun, 1993; 
Hannun and Obeid, 2008).  Additionally, ceramide is known to activate specific isoforms 
of PKC, including PKCζ (Fox et al., 2007; Hannun and Obeid, 2008), and endogenous 
S1P production induces activation of PKCε (Jin et al., 2002). While the activation of 
PKCs and CAPPs is well documented, these enzymes do not seem to be essential to all 
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sphingolipid signaling as several effects of sphingolipids are found to be PKC- and/or 
CAPP-independent.  
1.4.2 MAPK/ERK/JNK cascades 
Mitogen-activated protein kinases (MAPK) phosphorylate serine/threonine 
residues adjacent to proline in target proteins.  This super-family of kinases responds to a 
wide range of mitogenic and stress stimuli in the cardiovascular system and other tissues 
(Feuerstein and Young, 2000; Muslin, 2008).  MAPK fall into three major families: the 
extracellular-regulated kinases (ERK), the c-jun amino-terminal kinases (JNK), and the 
p38MAPK (Feuerstein and Young, 2000).  ERK primarily respond to mitogenic factors, 
whereas JNK and p38 MAPK respond to physiological stresses.  However, there is 
considerable overlap as several stimuli activate more than one pathway at a time.   
Sphingolipids stimulate signaling cascades regulated by MAPK pathways in 
cardiomyocytes (Feuerstein and Young, 2000; Sekiguchi et al., 1999) and other cell types 
(Zaslavsky et al., 2005; Giltiay et al., 2005).  Sphinosylphosphorylcholine (SPC), and to a 
lesser extent S1P, induce a hypertrophic growth response in cardiomyocytes that can be 
precluded by blockade with pertussis toxin (PTX) or the specific ERK1 inhibitor 
PD98059 (Sekiguchi et al., 1999).  Additionally, the cytoprotective effects of HDL and 
S1P have been linked to and ERK-dependent mechanism that is completely inhibited by 
PD98059 in human umbilical vein endothelial cells (Kimura et al., 2001).  Inflammatory 
mediators, specifically IL-1β, activate ERK through a ceramide-dependent manner in 
hepatocytes that can be mimicked by exogenous bacterial SMase (Giltiay et al., 2005).  
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However, other groups have reported that ceramide inhibits (Ghosh et al., 2002) or has no 
effect on (Pru et al., 2003) MAPK pathways.  While the mechanism for these differential 
effects remains unclear, there is some suggestion that ERK activation correlates with 
ceramide generation via sphingomyelin turnover in the plasma membrane while ERK 
inhibition correlates with de novo ceramide production (Giltiay et al., 2005; Ghosh et al., 
2002). 
1.4.3. PI-3K-Dependent Cascades 
PI-3K are a family of signal transducing enzymes that phosphorylate the three 
position hydroxyl group of the inositol ring of phosphatidylinositol.  The role of PI-3K in 
sphingolipid signaling cascades is largely unexplored.  However, there is evidence that 
S1P1 and/or S1P3 receptors are mediated through a PI-3K dependent pathway (Zhang et 
al., 2007b).  Additionally, ceramide-induced mitochondrial apoptosis has been shown to 
stimulate glycogen synthase kinase 3β through a PI-3K-dependent pathway (Lin et al., 
2007). 
1.4.4. EGFR/PDGFR-mediated cascades 
S1P has been identified as a ligand for the epidermal growth factor receptor 
(EGFR) family of G protein coupled receptors, although they couple to more than one G 
protein including Gi/o, Gq, and G12/13 (Kluk and Hla, 2002).  S1P increases tyrosine 
phosphorylation of EGFR and platelet-derived growth factor β receptors (PDGFβR) that 
is precluded by the Gi inhibitor PTX in vascular smooth muscle cells (Tanimoto et al., 
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2004b).  This transactivation could also be prevented by blockade of Src activation and 
ROS generation, and by cholesterol depletion.  By contrast, S1P-induced cell detachment 
in human embryonic kidney cells acts through PDGFR but not EGFR (Zaslavsky et al., 
2005).  S1P-induced cell detachment was Gi- and ERK-dependent and antagonized by the 
engagement of active state β1-integrin.  This suggests that S1P acts in an “inside-out” 
manner involving an endogenous, cell-surface S1P receptor pathway.  In fact, studies 
indicate that PDGFR can be tethered to S1P receptors (Alderton et al., 2001). 
1.4.5. ROS signaling 
Recently, the role of sphingolipids in reactive oxygen species (ROS) generation 
and signaling has come into focus.  In cardiomyocytes, there are two primary sources of 
ROS: NADPH oxidase (NOX) and the mitochondrial electron transport chain (ETC).  
The differential effects of sphingolipids on these two modulators of cellular ROS 
production will be discussed in the following sections. 
1.4.5.1.  Sphingolipids as mediators of NOX 
NOX is a membrane-bound enzyme that utilizes cytoplasmic NADPH and 
extracellular O2 to generate ROS and is involved in the phagocyte respiratory burst, 
immune function, cardiac hypertrophy, and atherogenesis.  Gathering evidence points to 
modulation of NOX by sphingolipids.  Ceramide increases the levels of GTP-bound Rac, 
a key step for the translocation of cytosolic components of NOX to the plasma 
membrane, in rat mesangial and kidney cells (Yi et al., 2004; Yi et al., 2006).  This 
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increase in NOX activity is attenuated with de novo ceramide synthesis inhibitors 
fumonisin B1 and myriocin (Yi et al., 2004; Yi et al., 2006), and inhibition of NOX 
and/or ceramide synthesis is associated with decreased hyperhomocysteine-induced 
glomerular injury (Yi et al., 2006).  Exogenous, short-chain ceramide also induces 
endothelial dysfunction attributable to NOX activation and subsequent peroxynitrite 
formation in small bovine coronary arteries (Zhang et al., 2003). 
CD95 ligand (CD95L) is a key upstream mediator of apoptosis and ROS 
production.  CD95L induces ceramide generation and p47phox phosphorylation in 
hepatocytes that is sensitive to blockade of SMase and PKCζ (Reinehr et al., 2005).  This 
process of NOX-derived ROS production is accompanied by upstream activation of Src 
kinases and JNK.  Similarly, hyperosmolarity-induced hepatocyte apoptosis was 
attenuated by inhibition of SMase and knockdown of A-SMase or p47phox (Reinehr et al., 
2006).  Recently, S1P was also shown to increase H2O2 production in murine fibroblasts 
through NOX activation (Catarzi et al., 2007).  This response was PI-3K- and PKC-
dependent and was similar to PDGF-induced NOX activation, suggesting a possible 
transactivation mechanism between PDGFR and S1P receptors. 
1.4.5.2.  Sphingolipids as mediators of mitochondrial ROS 
Increased mitochondrial ROS production associated with sphingolipids has been 
observed in experimental models of hypoxia/preconditioning (Lecour et al., 2006a; 
Lecour et al., 2006b), heart failure (Suematsu et al., 2003), and cardiac apoptosis and 
remodeling (Falluel-Morel et al., 2004; Suematsu et al., 2003).  Mitochondrial 
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dysfunction is also seen in human dyslipidemias (Vercesi et al., 2007).  The role of 
sphingolipids as modulators of mitochondrial function has been emphasized by the recent 
cloning of human mitochondrial ceramidase (El Bawab S. et al., 2000) and the 
localization of certain isoforms of SPHK to mitochondria (Maceyka et al., 2005).  
Pretreatment with exogenous, short-chain C2-ceramide reduces hypoxia-induced 
lactate dehydrogenase release in rat fibroblasts.  This cytoprotective effect is attributed to 
mitochondrial ROS generation as the ETC Complex I inhibitor rotenone attenuates the 
response, whereas inhibition of other sources of ROS, including NOX, xanthine oxidase, 
and nitric oxide synthase (NOS), had no effect (Lecour et al., 2006b).  Ceramide 
preconditioning provides a similar cytoprotective effect in ischemia/reperfusion of rat 
cardiac cells (Lecour et al., 2006a).  There is some evidence that ischemia/reperfusion-
induced ceramide generation and mitochondria damage is dependent on a MAPK/JNK 
signaling cascade, as JNK3-deficient mice are protected from ceramide accumulation and 
mitochondrial dysfunction (Yu et al., 2007).   
Exogenous C2-ceramide, but not the inactive analogue dihydro-C2-ceramide, 
directly inhibits the mitochondrial ETC at the level of Complex III (Gudz et al., 1997).  
C2-ceramide-induced increase in H2O2 is not attributable to the induction of the 
mitochondrial permeability transition pore because C2-ceramide did not induce 
mitochondrial swelling in isolated rat liver mitochondria (Garcia-Ruiz et al., 1997b).  An 
alternative mechanism for the action of ceramides is their assembly as pores.  Both short- 
and long-chain ceramides form large, high conductance permeation pathways in the outer 
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mitochondrial membrane that may contribute to the role of mitochondria in apoptosis 
(Siskind et al., 2006; Siskind et al., 2002; Siskind and Colombini, 2000). 
There is also evidence that ceramides of different chain lengths have differential 
roles in modulating mitochondrial function.  C2-ceramide stimulates cytochrome c 
oxidase and collapse of the mitochondrial membrane potential in isolated rat heart 
mitochondria (Di Paola M. et al., 2000).  By contrast, long-chain C16-ceramide inhibits 
cytochrome c oxidase activity and has negligible effect on mitochondrial membrane 
potential (Di Paola M. et al., 2000).  Additionally, C16-ceramide also inhibits formation of 
the mitochondrial permeability transition pore in isolated rat liver mitochondria 
(Novgorodov et al., 2008).  Obviously, sphingolipid modulation of mitochondria and 
mitochondrial ROS generation is complex and there are still many open questions 
regarding the mechanism of this regulation. 
1.5  Cardiac ICl,swell and its regulation 
Volume-sensitive Cl− current, ICl,swell, is elicited in cardiac myocytes by osmotic 
swelling (Tseng, 1992), hydrostatic inflation (Hagiwara et al., 1992), anionic amphipaths 
(Tseng, 1992), β1 integrin stretch (Baumgarten and Clemo, 2003), and in several models 
of cardiac disease.  In turn, ICl,swell modulates cardiac electrical activity, cell volume, 
apoptosis, and is implicated in ischemic preconditioning (Baumgarten et al., 2005; Duan 
et al., 2005; Hume et al., 2000).  Regulation of ICl,swell is complex and involves a number 
of signaling pathways.  Recently, reactive oxygen species (ROS) were identified as a 
downstream effector, and exogenous H2O2 elicits ICl,swell in cardiomyocytes (Browe and 
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Baumgarten, 2004; Browe and Baumgarten, 2006; Ren et al., 2008) and other cells 
(Haskew-Layton et al., 2005; Shimizu et al., 2004; Varela et al., 2004).  Upstream 
signaling molecules include Src family kinases (Walsh and Zhang, 2005; Du et al., 2004; 
Browe and Baumgarten, 2003d), focal adhesion kinase (Browe and Baumgarten, 2003d; 
Walsh and Zhang, 2005), protein tyrosine kinase (Sorota, 1995), angiotensin II (Ang II) 
(Ren et al., 2008; Browe and Baumgarten, 2004), epidermal growth factor receptor 
(EGFR) kinase (Du et al., 2004), and phosphoinositide 3-kinase (PI-3K) (Browe and 
Baumgarten, 2006; Ren et al., 2008).  Protein kinase C (PKC) also is implicated, 
although its role is controversial because it appears to inhibit (Duan et al., 1999) or 
activate ICl,swell (Gong et al., 2004; Duan et al., 1999).  Although the biophysical 
properties, pharmacology, and many of the regulatory pathways of ICl,swell have been 
extensively studied, the molecular identity of the channel remains elusive. 
Several biophysical properties are used to distinguish ICl,swell from other cardiac 
anion currents.  ICl,swell is outwardly rectifying and reverses near the chloride equilibrium 
potential (ECl) in either physiological or symmetrical Cl− gradients.  The current is time-
independent over the physiologic voltage range but partially inactivates at more positive 
potentials (Duan and Nattel, 1994; Shuba et al., 1996).  The time-dependent component 
can be blocked by addition of Cd2+ to the perfusate (Ren and Baumgarten, 2005).  ICl,swell 
is independent of cytoplasmic Ca2+ (Lemonnier et al., 2002) and the channel is permeant 
to other anions with the permeability sequence: I− > NO3− > Br−  > Cl− > Asp− (Hagiwara 
et al., 1992; Vandenberg et al., 1994). 
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Sorota (1994) compared block of ICl,swell in cardiac myocytes by several anion 
channel inhibitors.  ICl,swell is insensitive to Gd3+ (Clemo and Baumgarten, 1997), which is 
an inhibitor of mechanosensitive cation channels.  Although they also inhibit numerous 
cation channels and transporters, tamoxifen and DIDS (4,4’-diisothiocyanostilbene-2, 2’-
disulfonic acid) were found to be useful pharmacological instruments for identifying 
ICl,swell under conditions that isolate anion currents (Baumgarten and Clemo, 2003).  
Decher et al. (2001) demonstrated the highly selective block of ICl,swell by the ethacrynic 
acid-derivative DCPIB [4-(2-butyl-6,7-dichloro-2-cyclopentyl-indan-1-on-5-yl) oxobuty-
ric acid)].  At 10 µM, a concentration sufficient to fully block ICl,swell, this agent does not 
inhibit native CFTR or Ca2+-activated Cl− channels (ICl,Ca), exogenously expressed ClC-1, 
ClC-2, ClC-4, ClC-5, and ClC-K1 Cl− channels, and also has no effect on various K+, 
Ca2+, and Na+ channels (Decher et al., 2001).  ClC-3 also is unaffected by DCPIB (F. 
Lamb, personal communication to C.M. Baumgarten). 
ICl,swell also is implicated in several physiological and pathophysiological 
processes including cell volume regulation, migration, proliferation, differentiation, 
apoptosis, and ischemia-reperfusion injury (Baumgarten et al., 2005; Hume et al., 2000; 
Okada et al., 2009).  ICl,swell affects cardiac electrical activity and may play a role in 
mechanoelectircal feedback by antagonizing the effects of stretch-activated cation 
channels (Baumgarten and Clemo, 2003).  Since ICl,swell reverses between the resting 
membrane potential (Em) and the plateau phase potential in cardiomyocytes, ICl,swell 
activation depolarizes Em and acts to shorten APD (Hiraoka et al., 1998; Decher et al., 
2001).  This has important implications for arrhythmogenesis, as APD shortening due to 
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ICl,swell activation would tend to dampen cardiac afterdepolarizations and be protective 
against triggered arrhythmias.  Alternatively, shortening of APD may favor reentrant 
arrhythmias, such as atrial fibrillation, by reducing the minimum length conduction 
pathways needed to sustain them.  
ICl,swell may also influence cardiac function and arrhythmogenesis by its effects on 
cell survival.  Cl− channel inhibitors preclude the preconditioning seen with brief 
episodes of ischemia and hypoosmotic stress (Diaz and Wilson, 2006).  Apoptosis is also 
important during normal cardiomyocytes development and during ischemia and heart 
failure, and ICl,swell appears to be an important modulator of this process in heart and other 
cell types.  Block of ICl,swell prevents doxorubincin-induced apoptosis in cardiomyocytes 
(d'Anglemont de Tassigny et al., 2004).  The link between ICl,swell and apoptosis appears 
to be the apoptotic volume decrease (AVD).  AVD is an early required, Cl− flux-
dependent decrease in cell volume that precedes caspase-3 activation, cytochrome c 
release, and DNA fragmentation (Rasola et al., 1999; Okada and Maeno, 2001).  
Overexpression of the anti-apoptotic regulating protein Bcl-2 leads to upregualtion of 
ICl,swell in both dog kidney (Shen et al., 2002) and human prostate cancer epithelial 
(Lemonnier et al., 2004) cells.  Additionally, AVD is specifically associated with a ROS-
dependent activation of ICl,swell in HeLa cells (Shimizu et al., 2004).  
H2O2, a long-lived, cell permeable ROS, has been identified as a downstream 
mediator of ICl,swell in cardiac myocytes.  Scavenging H2O2 with catalase reverses β1-
integrin stretch-induced activation of ICl,swell (Browe and Baumgarten, 2004).  Moreover, 
the SOD mimetic MnTBAP that speeds conversion of superoxide (O2−•) to H2O2, 
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augments ACh-induced ICl,swell (Browe and Baumgarten, 2007).  ICl,swell also is activated 
by exogenous H2O2 with an EC50 of ~8 µM (Ren et al., 2008; Browe and Baumgarten, 
2004), and the site of action of H2O2 appears to be downstream from the volume-sensing 
mechanism because H2O2–induced current is insensitive to hyperosmotic shrinkage (Ren 
et al., 2008).  Potential sources for ROS in cardiomyocytes include NADPH oxidase 
(NOX) and the mitochondrial electron transport chain (ETC).  Both have been implicated 
in activation of ICl,swell (Browe and Baumgarten, 2004; Browe and Baumgarten, 2007; 
Ren et al., 2008) and will be discussed in detail in the following sections.  
1.5.1 NOX-derived ROS and upstream mediators 
1.5.1.1.  Integrin, FAK, and Src 
As ICl,swell is a mechanosensitive current, it is important to understand the 
mechanism of how mechanical forces are sensed and transmitted.  Integrins are 
heterodimeric proteins that provide a physical link between the extracellular matrix, 
plasma membrane, and the cytoskeleton that are important for signal transduction, cell 
migration, and a number of other cellular processes (Babbitt et al., 2002; Force et al., 
2002).  Integrins form cell adhesion complexes and co-localize with a number of 
signaling molecules, adaptor and regulating proteins, and cell surface receptors.  Focal 
adhesion kinase (FAK) and members of the Src kinase family are protein tyrosine kinases 
(PTK) and are important components of cell adhesion complexes that mediate integrin-
induced mechanotransduction (Shai et al., 2002; Babbitt et al., 2002).  Upon membrane 
stretch, FAK binds to the cytoplasmic domain of β1-intergins and autophosphorylates a 
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number of tyrosine residues, including Tyr397.  The SH2 domain of Src binds then to 
Tyr397 of FAK and the activated complex recruit a number of signaling molecules 
including protein kinase C (PKC), phosphoinositide-3 kinase (PI-3K), and protein 
phosphatases and stimulate a number of downstream signaling cascades (Parsons, 2003).   
β1-integrin stretch has been shown to play an important role in cardiac cell 
growth and remodeling during hypertrophy (Pham et al., 2000).  β1-integrins, FAK, and 
Src are important in the regulation of ICl,swell, and β1-integrin stretch elicits ICl,swell under 
isoosmotic conditions (Browe and Baumgarten, 2003d).  β1-integrin-induced activation 
of ICl,swell is blocked by both genistein, a non-specific PTK inhibitor, and protein 
phophatase 2 (PP2), a selective Src inhibitor (Browe and Baumgarten, 2003d).  The role 
of Src in ICl,swell regulation is complex, however, and varies depending on the stimuli.  In 
contrast to its effect following β1-integrin stretch, PP2 substantially enhances ICl,swell 
induced by osmotic swelling in both atrial and ventricular myocytes (Du et al., 2004; Ren 
and Baumgarten, 2005; Walsh and Zhang, 2005). The mechanisms underlying the 
differential regulation of ICl,swell by FAK and Src remains unclear. 
1.5.1.2.  Ang II and Ang II receptors 
Upon mechanical stretch, cardiomyocytes release a number of autocrine/paracrine 
factors, including angiotensin II (Ang II) and endothelin-1 (ET-1), which bind to their 
surface receptors and induce a number of downstream signaling cascades (Ruwhof et al., 
2001).  Additionally, stretch induces Ang II receptor type 1 (AT1R) activation exclusive 
of Ang II binding, suggesting Ang II may not be required for AT1R-mediated 
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mechanotransduction (Zou et al., 2004).  It is not unexpected then, that Ang II and AT1R 
play a role in the regulation of ICl,swell in cardiomyocytes.  This is evidenced by the 
observations that exogenous Ang II elicits ICl,swell under isoosmotic conditions and that 
competitive AT1R antagonists, losartan and eposartan, inhibit osmotic swelling- and β1-
integrin stretch-induced ICl,swell (Ren and Baumgarten, 2005; Browe and Baumgarten, 
2004). 
1.5.1.3.  Endothelin-1 
Endothelins (ETs) are a family of 21-amino acid peptides that includes three 
primary isoforms: ET-1, ET-2, and ET-3.  ET-1 is the major isoform responsible for the 
cardiovascular effects of this protein family (Kedzierski and Yanagisawa, 2001).  ET-1 
interacts with two G protein coupled receptors subtypes, ETA and ETB, both of which are 
heterogeneously expressed in heart (Russell and Molenaar, 2000).   
ET-1 elicits ICl,swell in atrial cardiomyocytes via activation of ETA receptors (Deng 
and Baumgarten, 2009).  ET-1-induced ICl,swell is abrogated by block of EGFR kinase 
with AG1478 and inhibition of PI-3K with both wortmannin and LY294002.  
Additionally, dismutation of H2O2 with the glutathione peroxidase mimetic ebselen 
completely attenuates ET-1-induced current (Deng and Baumgarten, 2009).  These results 
suggest that the action of ET-1 in this cascade is upstream of EGFR kinase and PI-3K 
activation and generation of ROS. 
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1.5.1.4.  EGFR kinase 
Epidermal growth factor receptor (EGFR) kinase has been identified as a common 
element in signaling cascades induced by changes in cell volume (Lezama et al., 2005; 
Browe and Baumgarten, 2006), TNFα (Tetreault et al., 2008), integrins (Moro et al., 
2002), and AT1Rs (Shah and Catt, 2003).  EGFRs have also been implicated in the 
regulation of ICl,swell (Baumgarten, 2006; Du et al., 2004; Ren et al., 2008).  Exogenous 
EGF elicits ICl,swell under isoosmotic conditions and EGFR kinase inhibitors block ICl,swell 
activation induced by osmotic swelling, β1-integrin stretch, and Ang II (Ren et al., 2008; 
Browe and Baumgarten, 2006). 
1.5.1.5.  PI-3K 
PI-3K are a family of signal transducing enzymes that phosphorylate the three 
position hydroxyl group of the inositol ring of phosphatidylinositol.  They are 
heterodimers comprised of a p110 catalytic subunit and one of a number of different 
regulatory subunits.  In the heart, the predominant isotypes are p110-p85, activated by 
PTK, and p110-p101, activated by a G protein mechanism (Pretorius et al., 2009; Till et 
al., 2000).  Myocardial PI-3K activation is induced by osmotic swelling (Ren et al., 2008; 
Tilly et al., 1996), myocardial stretch (Kim et al., 2002), and integrin/FAK stimulation 
(Franchini et al., 2000).  PI-3K is coupled to EGFR and mediates downstream signaling 
induced by EGFR and AT1R activation (Browe and Baumgarten, 2006; Kippenberger et 
al., 2005; Ren et al., 2008).  In cardiomyocytes, the PI-3K inhibitors wortmannin and 
LY294002 block ICl,swell activation induced by EGF, β1-intergrin stretch, and osmotic 
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swelling (Browe and Baumgarten, 2006; Ren et al., 2008).  This suggests that PI-3K is 
downstream from EGFR, AT1R, and the volume-sensing mechanism of ICl,swell. 
1.5.1.6.  NOX 
NADPH oxidase (NOX) is a membrane-bound enzyme that generates ROS from 
cytosolic NADPH and is involved in the respiratory burst, cardiac hypertrophy, and 
atherogenesis.  NOX2 is the primary isoform expressed in cardiomyocytes, although 
expression of NOX4 has also been reported (Byrne et al., 2003a).  NOX2 is comprised of 
six subunits: a transmembrane flavocytochrome b558 complex consisting of a large 
gp91phox subunit, a smaller p22phox subunit, cytosolic p47phox and p67phox subunits, and the 
GTP-binding protein Rac (Bedard and Krause, 2007; Wallach and Segal, 1996).  NOX2 
becomes functionally active when Rac and the cytosolic subunits translocate from the 
cytosol to the plasma membrane and assemble with gp91phox and p22phox.  This process is 
mediated by a number of signaling molecules, including PTK such as Src, PKC, and PI-
3K (Bedard and Krause, 2007).  The fully assembled, functional complex transfers 
electrons across the plasma membrane, resulting in production of O2−• that is then rapidly 
converted to H2O2 spontaneously and through the action of SOD (Bedard and Krause, 
2007).  NOX stimulation also leads to downstream signaling cascades, including 
activation of MAPK and ERK1/2 (Bedard and Krause, 2007). 
NOX is a required component of ICl,swell activation induced by β1-intergrin stretch, 
osmotic swelling, EGF, ET-1 and Ang II.  ICl,swell evoked by these stimuli is completely 
inhibited by block of NOX with the membrane-permeant fusion peptide gp91ds-tat, 
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diphenyleneiodonium (DPI), 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), or 
apocynin (Browe and Baumgarten, 2006; Ren et al., 2008). 
1.5.2. Mitochondria-derived ROS and upstream mediators 
Mitochondria, through the function of the ETC, are another source of ROS in 
cardiomyocytes.  Increased mitochondrial ROS production has been observed in 
experimental models of heart failure (Giordano, 2005; Ide et al., 1999), 
ischemia/reperfusion injury (Vanden Hoek et al., 1998; Giordano, 2005), myocardial 
infarction (Vanden Hoek et al., 1998; Ide et al., 2001; Giordano, 2005; Byrne et al., 
2003b), and cardiac apoptosis and remodeling (Byrne et al., 2003b; Kumar and Jugdutt, 
2003).  Mitochondrial ROS production at ETC Complex III is seen very early during 
global ischemia and leads to depletion of cardiolipin from the mitochondrial membrane 
and loss of cytochrome c (Chen et al., 2008).  Additionally, mitochondrial ROS are 
reported to play a role in the slow force response to myocardial stretch and the positive 
inotropic effects of Ang II (Caldiz et al., 2007; De Cavanagh et al., 2009).   
Acetylcholine (ACh) was also shown to stimulate ROS production via muscarnic 
receptors (Yao et al., 1999).  This process is dependent on Src, PI-3K, and opening of 
mitochondrial ATP-sensitive K+ (mitoKATP) channels (Oldenburg et al., 2003).  
Preliminary data indicate that exogenous ACh elicits ICl,swell via a mitochondrial ROS-
dependent mechanism.  ACh-induced ICl,swell is completely inhibited by the mitoKATP 
inhibitor 5-hydroxydecanoic acid (5-HD) and the mitochondrial ETC Complex I inhibitor 
rotenone (Browe and Baumgarten, 2007).  Additionally, it has been shown that certain 
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stimuli, such as certain HIV protease inhibitors, activate ICl,swell via mitochondrial ROS 
production independent of NOX (Deng et al., 2009).   
1.5.3. Crosstalk between NOX and mitochondria 
There are two populations of mitochondria in cardiomyocytes: those found near 
the sarcolemmal membrane, known as subsarcolemmal mitochondria; and those 
interspersed between the myofibrils, known as interfibrillar mitochondria.  The proximity 
of subsarcolemmal mitochondria to the plasma membrane raises the possibility of 
crosstalk between NOX and mitochondria.  There is evidence that such an interaction 
occurs, as Ang II and ET-1 induce ROS via NOX and mitochondria (De Giusti et al., 
2008; De Giusti et al., 2009).  Inhibition of either NOX or mitoKATP channels blocked 
these responses.  Additionally, inhibition of NOX assembly or blockade of mitoKATP 
channels abrogate the effects of preconditioning, lipid peroxidation, activation of MAPK 
pathway, and apoptosis in cardiomyocytes (Zhang et al., 2007a; Caldiz et al., 2007; 
Bedard and Krause, 2007).  Block of either source completely ameliorates these 
responses, indicating that NOX and mitochondria may act in series rather than in parallel.  
Mitochondrial ROS may be induced by NOX-derived ROS and/or by paracine induction 
due to ROS from neighboring mitochondria (Aon et al., 2003; Zorov et al., 2006).  
Recent evidence indicates that mitochondria ROS generation may be downstream of 
NOX in ICl,swell activation due to some stimuli, as the ETC Complex III inhibitor 
antimycin A and the mitoKATP agonist diazoxide elicit gp91ds-tat-insensitive ICl,swell 
activation (Deng and Baumgarten, 2009). 
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1.5.4. PKC and ERK1/2 
Aside from ROS, regulation of ICl,swell by PKC, ERK1/2, and Rho/Rho kinase has 
been observed.  PKC has contrasting effects in different cell types.  PKC antagonizes the 
action of serine/threonine phosphatases and inhibits ICl,swell activation in rabbit atrial 
myocytes (Duan et al., 1995).  In normal canine and rabbit cardiomyocytes, ICl,swell 
activation is protein phosphatase 2a (PP2a)-dependent and Ca2+–independent (Clemo et 
al., 1999).  In heart failure cells, ICl,swell activation is modulated by the Ca2+–dependent 
phosphatase calcineurin (PP2b) (Clemo et al., 2000).  By contrast, PKC stimulates ICl,swell 
in canine atrial and murine ventricular cells (Du and Sorota, 1999; Gong et al., 2004).  
The MAPK pathway has also been implicated in ICl,swell regulation.  Inhibition of ERK1/2 
prevented the persistent activation of ICl,swell in heart failure cardiomyocytes (Clemo and 
Baumgarten, 1999).   
1.6 HL-1 cells as a potential tool to investigate ICl,swell 
HL-1 cells are an immortalized murine atrial cell line derived from a primary 
culture of SV40 large T antigen-induced atrial tumors.  This cell line may be repeatedly 
passaged while maintaining their contractile ability and their morphological and 
electrophysiological characteristics (Claycomb et al., 1998).  HL-1 cells have been used 
to study cellular signaling (McWhinney et al., 2000), calcium handling (George et al., 
2003), and electoral properties (Walker et al., 2007; Akhavan et al., 2003) of 
cardiomyocytes.  They have also been used as a model for various pathological states, 
including hypoxia (Nguyen and Claycomb, 1999; Cormier-Regard et al., 1998), apoptosis 
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(Kim et al., 2003; Carlson et al., 2002), ischemia/reperfusion injury (White et al., 2004; 
Ruiz-Meana et al., 2006; Ruiz-Meana et al., 2003), and rapid pacing-induced electrical 
remodeling (Yang et al., 2005).   
 The rennin-angiotensin system machinery is expressed in HL-1 cardiomyocytes 
and Ang II induced expression of L-type Ca2+ channels via a NOX-dependent pathway 
(Tsai et al., 2008; Tsai et al., 2007).  Moreover, preliminary data from this laboratory 
demonstrates that ICl,swell is present in HL-1 myocytes and is regulated by ET-1 signaling 
and by ROS generated by NOX and mitochondria in a similar manner to native 
cardiomyocytes (Deng and Baumgarten, 2009).  Therefore, this cell line is a valuable tool 
for studying ICl,swell . 
1.7  Aims of the present study 
 Based on evidence in that ICl,swell is activated by ROS and ceramides elicit ROS 
production by NADPH oxidase and mitochondria, we hypothesized that sphingolipids 
would activate cardiac ICl,swell under isosmotic conditions by a ROS-dependent pathway.  
To test this hypothesis we used a combination of whole-cell patch clamp to measure ionic 
currents, flow cytometry to measure ROS production, and tandem mass spectroscopy to 
measure membrane lipid composition.  Five specific aims were addressed.  The first aim 
was to determine if exogenous, membrane-permeant, short-chain synthetic ceramide 
activates ICl,swell in rabbit ventricular myocytes.  The second aim was to determine if 
endogenous long-chain ceramides activate ICl,swell.  Bacterial sphingomyelinase (SMase) 
was used to generate native ceramides, and with the assistance of collaborators, 
membrane sphingolipid content was measured with tandem mass spectrometry.  The third 
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aim was to examine the role of ROS in the signaling cascade leading to SMase-induced 
ICl,swell.  The fourth aim was to determine the role of ceramide metabolites in the 
activation of ICl,swell.  The fifth aim was to use flow cytometry to determine if SMase-
induced ROS production.  HL-1 myocytes were used to address this last aim. 
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Chapter 2 
MATERIALS and METHODS 
 
 
2.1. Rabbits and ventricular myocyte isolation 
Ventricular myocytes were isolated from adult New Zealand white rabbits (~3 
kg).  The animals were first sedated with a combination of acepromazine (1 mg/kg, IM) 
and xylazine (5 mg/kg, IM).  This was followed by ketamine (35 mg/kg, IM) to induce a 
surgical plan of anesthetic.  Prior to sacrifice (approximately 5 min), heparin (1000 U, 
IV) was administered to the animals via the ear vein to prevent clotting within the 
coronary arteries.  When the animal is non-responsive to toe-pinch and corneal contact, a 
midline sternotomy is performed and the heart is removed.  Following excision, hearts 
were affixed to a Langendorff perfusion apparatus, where the heart then undergoes 
retrograde perfusion via the aorta.  First, a Ca2+-containing, oxygenated (100% O2) 
Tyrode solution was perfused to maintain contraction and clear the coronary vessels of 
blood.  Next, an oxygenated, EGTA-containing Ca2+-free Tyrode solution was perfused 
in order to chelate any residual Ca2+, as enzymatic digestion is sensitive to free Ca2+ 
concentration.  Then, after a small amount (~40 mL) of nominally Ca2+-free Tyrode 
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solution was perfused to flush out EGTA, the coronary arteries were perfused with 
enzyme solution that was recirculated.  The heart was digested on the column for 20 – 24 
min. and was then removed and mincied (~1 mm3).  The tissue was placed in modified 
Kraft-Bruhe (KB) solution and gently agitated by stirring for 3 – 5 min. to release 
individual myocytes from the tissue.  Subsequently, the myocytes were washed in fresh 
KB solution twice and allowed to quiesce for ~1 hr before the study was begun.   
Tyrode solution for cell isolation contained (in mM): 130 NaCl, 5 KCl, 1.8 CaCl2, 
0.4 KH2PO4, 3 MgCl2, 5 HEPES, 15 taurine, 5 creatine, 10 glucose (pH 7.25, adjusted 
with NaOH).  For Ca2+-free Tyrode solution, CaCl2 was replaced with 0.1 mM Na2-
EGTA.  Enzyme solution contained 0.45 mg/mL collagenase (Cls 4, Worthington) and 
0.015 mg/mL pronase (Type XIV, Sigma-Aldrich) in nominally Ca2+-free Tyrode 
solution without EGTA.  Isolated myocytes were washed and stored in a modified KB 
solution that contained (in mM): 120 K-glutamate, 10 KCl, 10 KH2PO4, 1.8 MgSO4, 0.5 
K2-EGTA, 10 taurine, 10 HEPES, 20 glucose 13.7 mannitol (pH 7.20, adjusted with 
CsOH).  Experiments were conducted within 12 h of myocyte isolation.  Cells chosen for 
experiments were rod-shaped with clear striations, quiescent, and free of membrane blebs 
or other morphological irregularities.   
2.2. Culture of HL-1 cells 
HL-1 cardiac myocytes (passage 67 to 81), an immortalized mouse atrial cell line 
(Claycomb et al., 1998), were also studied.  Tissue culture flasks were first coated with a 
gelatin (0.02%)/fibronectin (0.5%) mixture (2 mL in T25 or 6 mL in T75 flask) and 
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incubated overnight at 37°C.  HL-1 cells were culture in pre-coated flasks using 
Claycomb medium (JRH Biosciences, Lenexa, KS) supplemented with 10% fetal bovine 
serum (Sigma-Aldrich), 100 µg/mL penicillin/streptomycin, 0.1 mM norepinephrine 
(Sigma-Aldrich), and 2 mM L-glutamine (Invitrogen, Carslbad, CA).  The cells were kept 
at 37°C in an atmosphere of 5% CO2 and 95% air at a relative humidity of approximately 
95%.  Once the cells reached confluence, they were passaged in a 1:2 split.  To split the 
HL-1 cells, they were briefly rinsed with DPBS and then incubated with 0.05% 
trypsin/EDTA (3 mL for T25 or 6 mL for T75 flask) at 37°C for 3 – 5 min until the cells 
dissociated from the flask surface.  An equal amount of soybean trypsin inhibitor (25 
mg/100 mL PBS) was added directly to the flask and then the contents were transferred 
to a 15 mL centrifuge tube.  The cells were centrifuged at 1100 rpm for 5 min and the 
supernatant was removed by aspiration and the pellet was gently suspended in 3 mL of 
supplemented Claycomb medium.  For culture preparation, the cells were transferred to 
gelatin/fibronectin-coated flasks.  For electrophysiological studies, the cells were 
transferred to a 15 mL centrifuge tube. 
2.3. Experimental solutions and drugs 
Bath and pipette solutions were designed to isolated Cl− current.  Isosmotic bath 
solution (1T; 300 mOsm/kg; T, times isosmotic) contained (in mM) : 90 N-methyl-D-
glucamine-Cl, 3 MgCl2, 10 HEPES, 10 glucose, 5 CsCl, 0.5 CdCl2, 70 mannitol (pH 7.4, 
adjusted CsOH).  Hyperosmotic bath solution (1.5T, 450 mOsm/kg) had the same 
composition except for an additional 150 mM mannitol, and hypoosmotic bath solution 
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(0.7T, 230 mOsm/kg) contained no mannitol.  For experiments with SMase, 6 mM 
MgCl2 was added to augment enzymatic activity, with mannitol concentrations adjusted 
accordingly.  Pipette solution contained (in mM): 110 Cs-Aspartate, 20 TEA-Cl, 5 Mg-
ATP, 0.1 Tris-GTP, 0.15 CaCl2, 8 Cs2-EGTA, 10 HEPES (pH 7.1, adjusted with CsOH).  
To make symmetrical Cl− pipette solution, 82 mM CsCl replaced an equal amount of Cs-
Aspartate.  Osmolarity was verified by measurement of freezing-point depression.    
Stock solutions of D-erythro-C2-ceramide (C2-Cer; 5 mM; Biomol), D-erythro-
dihydro-C2-ceramide (C2-H2Cer; 5 mM; Biomol), ebselen (15 mM, Calbiochem), 
rotenone (20 mM; Sigma-Aldrich), apocynin (500 mM; Sigma-Aldrich), PD98059 (10 
mM; Calbiochem), U0126 (1 mM; Biomol), diphenyliodonium (DPI, 60 mM; Sigma-
Aldrich), and DCPIB (20 mM; Tocris) in DMSO and tamoxifen (20 mM; Sigma-
Aldrich), 5-hydroxy-decanioc acid (5-HD, 500 mM; MP Biochemicals), DL-threo-
dihydrosphingosine (10 mM; Cayman), and (1S,2R-D-erythro-2-N-myristoylamino)-1-
phenyl-1-propanol (D-erythro-MAPP, 10 mM; Cayman) in ethanol were frozen (−20°C) 
in aliquots until use.  The NOX inhibitor gp91ds-tat was synthesized by the Tufts 
University Core Facility.  Peptide stocks of gp91ds-tat were made in 150 mM NaCl plus 
10 mM acetic acid and frozen (–20°C) in aliquots until use.  Stock solutions of Mg2+-
dependent, neutral bacterial sphingomyelinase, also known as SMase C, from B. cereus 
(50 U/mL, in H2O; Sigma-Aldrich) were stored in aliquots at 4°C until use.   
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Although it is not present physiologically, application of exogenous synthetic short-chain 
C2-Cer was employed because it is membrane permeant and is adequately soluble in the 
serum-free experimental solutions without forming micelles.  On the other hand, bacterial 
SMase generates native long-chain ceramides from membrane sphingomyelinase and 
may better represent ceramide accumulation in physiologic and pathophysiologic 
settings. 
2.4. Whole cell patch clamp and electrophysiological recordings  
Ventricular myocytes were scattered on a glass-bottomed chamber and placed on 
the stage of an inverted light microscope (Nikon) with Hoffman modulation optics, and a 
high resolution video camera (CCD72; Dage-MTI) was used to visualize individual cells.  
Cells were suprafused with bath solution at 2−3 mL/min, and recordings were made at 
room temperature (22–23°C).  Pipettes were pulled from 7740 thin-walled borosilicate 
capillary tubing (Sutter) and fire polished to a final tip diameter of approximately 3 µm 
with a resistance in bath solution of 2 – 4 MΩ.  Membrane currents were recorded in the 
whole-cell configuration using an Axopatch 200B amplifier and Digidata 1322A data 
acquisition system (Axon).  A 3-M KCl agar bridge served as the ground electrode.  Seal 
resistances of 2 – 20 GΩ typically were obtained, and membrane capacitance routinely 
was measured.  All membrane potential data were corrected for the measured liquid 
junction potential, and myocytes were dialyzed with pipette solution for 8 – 10 min prior 
to the start of recording.  Voltage clamp protocols and data acquisition were controlled by 
pClamp 8.2.  Successive 500-ms voltage steps were implemented from a holding 
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potential of −60 mV to test potentials ranging from −100 to +60 mV in +10 mV 
increments.  Membrane currents were low-pass filtered at 2 kHz and digitized at 5 kHz.  
Representative current traces were low-pass filtered at 500 Hz for presentation, and 
displayed I-V curves are from the corresponding current traces.  To minimize variability, 
experiments were designed to use cells as their own controls. 
2.5 ROS detection by flow cytometry 
ROS production was assessed in HL-1 cells rather than freshly isolated myocytes, 
as damaged myocytes are inevitably included in freshly isolated preparations.  ROS was 
detected with C-H2DCFDA-AM [6-carboxy-2’,7’;-dichlorodihydro-fluorescein diacetate 
di(acetoxy-methyl ester)] (Invitrogen), which is converted to carboxy-H2DCF, a non-
fluorescent derivative, by intracellular esterases.  Carboxy-H2DCF remains in the 
cytoplasm and is oxidized to fluorescent carboxy-DCF by intracellular ROS.  Confluent 
HL-1 cells were incubated with C-H2DCFDA-AM (2.5 or 5 µM) for 30 min at 37°C, 
washed twice with DPBS, and isolated using the splitting procedure described previously.  
Single myocyte suspensions in isoosmotic bath solution were analyzed using a EPICS XL 
cytometer (Beckman Coulter).  The geometric means of the gated fluorescence 
distributions (excitation: 485 nm; emission: 520 nm) were calculated using the EXPO32 
software (Beckman Coulter).  After gating, 20,000 to 40,000 cells contributed to each 
fluorescence distribution.  Fluorescence histograms (1024 bins) were exported to Excel 
(Microsoft) and plotted in SigmaPlot (Systat) after filtering (5 point running average, 
replotted in 512 bins).  This gives plots that were comparable to those displayed with the 
commonly used but ill-defined smoothing function in EXPO32. 
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2.6 Tandem mass spectrometry 
Ventricular myocytes were subjected to the relevant treatment, and harvested in 
1T bath solution as described above.  An aliquot of cells were taken for standardization 
(total protein).  Lipids were extracted from 500 µL of the remaining cells as described by 
Wijesinghe et al. (2009) and Merrill et al. (2005) with slight modifications.  Briefly, 2 
mL of methanol and 1 mL of chloroform was added to 500 µL of the cell 
suspension,together with an internal standard containing 500 pmol of the following: d17:1 
sphingosine, sphinganine, sphingosine-1-phosphate and sphinganine-1-phosphate, 
d18:1/12:0 ceramide, ceramide-1-phosphate, sphingomyelin and glucosylceramide.  The 
mixture was sonicated and incubated at 48°C overnight.  The following day, extracts 
were subjected to base hydrolysis for 2 hr at 37°C using 150 µL of 1.0 M methanolic 
KOH.  Following base hydrolysis the extract was completely neutralized by the addition 
of glacial acetic acid.  The neutralization was confirmed with pH paper.  Half of the 
extract was dried down and brought up in reversed phase sample buffer (60%A:40%B).  
To the remainder of the extract, 1 mL of chloroform and 2 mL of water were added, and 
the lower phase was transferred to another tube, dried down and brought up in normal 
phase sample buffer (98%A:2%B).  Sphingosine, sphinganine, sphingosine-1-phosphate 
sphinganine-1-phosphate and ceramide-1-phosphate were quantified via reversed phase 
HPLC ESI-MS/MS using a Discovery C18 column attached to a Shimadzu HPLC  
(20AD series) and subjected to mass spectrometric analysis using a 4000 Q-Trap 
(Applied Biosystems) as described (Wijesinghe et al., 2009).  Ceramides, sphingomyelins 
and monohexosyl ceramides were quantified via normal phase HPLC ESI-MS/MS using 
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an amino column (Sigma) as described (Merrill, Jr. et al., 2005).   
2.7 Statistics 
Summary patch clamp data are reported as mean ± SEM; n denotes the number of 
cells.  Mean currents are expressed as current density (pA/pF) to account for differences 
in myocyte surface membrane area, and selected paired comparisons are expressed as a 
percentage or as the intervention-induced difference current.  Statistical analysis was 
executed using SigmaStat 3.11 (Systat).  For multiple comparisons, a One Way or a One 
Way Repeated Measures Analysis of Variance was performed, followed by a Student-
Newman-Keuls test.  In both cases, P < 0.05 was taken as significant.  Geometric means 
of florescence histogram data were not normally distributed and were analyzed using 
Kruskal-Wallis One Way Analysis of Variance on Ranks followed by comparison to 
background florescence by Dunn's method.  Non-linear curve fits were done in SigmaPlot 
10.0 (Systat).   
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Chapter 3 
RESULTS 
 
 
3.1. Exogenous ceramide activates a Cl− current resembling ICl,swell 
As shown in Figure 2, C2-ceramide (C2-Cer; 2 µM, 10 – 12 min), a membrane-
permeant, short-chain ceramide analogue, activated an outwardly-rectifying Cl− current 
with a reversal potential near the Cl− equilibrium potential (ECl), −43 mV.  Current at 
+60 mV increased by 0.70 ± 0.09 pA/pF (n = 15, P < 0.001), from 0.87 ± 0.13 to 1.57 ± 
0.22 pA/pF, and a C2-Cer-induced current was observed in >90% of the cells tested.  
Addition of DCPIB (10 µM, 12–15 min), a highly selective ICl,swell blocker, inhibited the 
C2-Cer-induced Cl− current by 76 ± 8 % (n = 6, P < 0.001) in the continued presence of 
C2-Cer, and there was no significant difference between the DCPIB-inhibited and control 
currents (P = 0.24).  Furthermore, the C2-Cer-induced current was steeply concentration 
dependent with an EC50 of 0.5 µM and Hill coefficient of 5.  The physiological range for 
native ceramide in many cell types is 1 – 5 µM, (Hannun, 1996) although local 
concentrations under some conditions may be greater.(Hannun and Obeid, 2008)  
Because C2-Cer is a short-chain synthetic ceramide, its concentration dependence may  
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Figure 2:  C2-ceramide (C2-Cer) elicited a Cl− current in rabbit ventricular 
myocytes that resembled ICl,swell.  (A) Families of currents under control conditions 
(Ctrl), and after treatment with 2 µM C2-Cer for 10 min, and after addition of DCPIB 
(+DCPIB; 10 µM) in the continued presence of C2-Cer.  Holding potential, −60 mV mV; 
test potentials, −100 to +60 mV. (B) Current-voltage (I-V) relationships for A.  (C) 
Normalized currents at +60 mV.  C2-Cer increased Cl− current by 0.70 ± 0.09 pA/pF (n = 
14, P < 0.001).  The C2-Cer-induced current was inhibited by 76 ± 8% (n = 6, P < 0.001) 
by the ICl,swell-specific inhibitor DCPIB, and the remaining current was not significantly 
different than control (P = 0.24).  (D) Concentration-response relationship  for 0.2 (n = 
3), 0.6 (n = 3), 2 (n = 15) and 20 µM (n = 4) C2-Cer.  Data were fit (solid line) with an 
EC50 of 0.5 µM and a Hill coefficient of 5.   
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not match that of native ceramides.  No change in membrane capacitance was observed in 
individual cells treated with C2-Cer (data not shown).  Under control conditions, the 
background current usually displayed modest outward rectification, and its amplitude at 
+60 mV varied somewhat from cell-to-cell.  Such variation has been noted previously 
and likely reflects partial activation of ICl,swell under control conditions. 
Outward rectification in symmetrical Cl− solutions is a characteristic of ICl,swell 
that distinguishes it from several other Cl− currents, including CFTR and Ca2+-activated 
Cl− currents.(Hume et al., 2000)  Under symmetrical Cl− conditions (Figure 3), C2-Cer 
(2 µM, 10–12 min) elicited current that outwardly rectified and reversed at 0 mV.  At 
+60 mV, C2-Cer increased current density by 1.30 ± 0.32 pA/pF (n = 6, P < 0.01), from 
1.03 ± 0.23 to 2.33 ± 0.52 pA/pF.  Taken together, outward rectification in both 
physiological and symmetrical Cl− solutions and block by DCPIB are diagnostic for 
ICl,swell.   
Alterations in membrane curvature due to asymmetric insertion of amphipathic 
molecules into the outer or inner leaflets of the plasma membrane are known to mimic 
changes in cell volume by altering membrane tension and shape and can activate ICl,swell 
(Tseng, 1992).  To exclude the possibility that C2-Cer activated ICl,swell via alteration of 
membrane curvature or other non-specific mechanisms, we used dihydro-C2-ceramide 
(C2-H2Cer), an analogue of C2-Cer that is inactive in ceramide signaling (Bielawska et 
al., 1993) but should exert similar mechanical effects on membranes.  As depicted in 
Figure 4, C2-H2Cer failed to activate current above control (n = 6, P = 0.94).  In order to  
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Figure 3:  C2-Cer (2 µM, 10 min) activated outwardly-rectifying Cl− current in 
symmetrical Cl−.  (A) Families of currents in symmetrical Cl−, and (B) I-V relationships.  
C2-Cer-induced current reversed near 0 mV.  (C) Current densities at +60 mV.  C2-Cer-
induced current was 1.30 ± 0.35 pA/pF (n = 6, P < 0.01).  Outward rectification in 
symmetrical Cl− and block by DCPIB (Figure 1) indicate that C2-Cer activated ICl,swell in 
ventricular myocytes. 
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Figure 4:  C2-dihydroceramide (C2-H2Cer), a metabolically inactive analogue of C2-
Cer, did not alter membrane current but C2-Cer elicited ICl,swell in the same cell.  (A) 
Typical currents at +60 mV.  (B)  Exposure to inactive C2-H2Cer (2 µM, 10 min) failed to 
elicit Cl− current (−4 ± 5%, n = 6, ns), whereas C2-Cer (2 µM, 10 min) subsequently 
stimulated current in the same cell (n = 4, P < 0.01).  Activation by C2-Cer but not C2-
H2Cer indicates that C2-Cer elicited ICl,swell via its normal signaling cascade rather than by 
a non-specific mechanism. 
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verify that ICl,swell was present in cells that were unresponsive to C2-H2Cer, C2-Cer was 
then added.  In the same cells, C2-Cer evoked ICl,swell (n = 4, P < 0.01).  Activation by C2-
Cer but not C2-H2Cer suggests that ICl,swell was elicited via a ceramide signaling pathway 
rather than by a non-specific mechanism. 
3.2 Endogenous ceramide generation is sufficient to activate ICl,swell 
 
Bacterial SMase is a neutral, Mg2+-dependent enzyme that acts specifically at the 
plasma membrane to convert sphingomyelin to long-chain ceramides that are native to 
the cell.  Bacterial SMase (0.03 U/mL, 15–18 min), like exogenous C2-Cer, evoked an 
outwardly rectifying Cl− current in >90% of the cells tested, and the current at +60 mV 
increased by 1.01 ± 0.05 pA/pF (n = 75, P < 0.001), from 1.22 ± 0.07 to 2.23 ± 0.10 
pA/pF (Figure 5A,B).  The SMase-induced current was reversible with 20 min of 
washout in control bath solution in each of the cells tested (n = 3, P < 0.05) (Figure 5C).  
No change in membrane capacitance was observed in individual cells treated with 
bacterial SMase (data not shown).   
Two blockers of ICl,swell inhibited bacterial SMase-induced current.  DCPIB suppressed 78 
± 6 % (10 µM, n = 7,  P < 0.01) of the current, and the remaining current was not 
significantly different than that in control (P = 0.90) (Figure 5B).  Increasing the 
concentration of DCPIB to 30 µM did not reduce the SMase-induced current further (81 
± 6 %; n = 4, P < 0.01 vs control; ns vs 10 µM DCPIB).  Tamoxifen (10 µM, 5 – 8 min) 
also was effective in blocking the SMase-induced Cl− current (Figure 6); it decreased  
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Figure 5:  Bacterial sphingomyelinase (SMase) reversibly activated ICl,swell.  (A) I-V 
relationships for Cl− current elicited by SMase (0.03 U/mL, 15 − 18 min) and inhibition 
by DCPIB (10 µM).  (B) SMase increased Cl− current by 1.1 ± 0.1 pA/pF at +60 mV (n = 
30).  DCPIB (10 or 30 µM) suppressed 78 ± 6% (n = 7) or 81 ± 6% (n = 4), respectively  
(P < 0.01 for both).  (C) Effect of SMase reversed on washout (18 − 20 min, n = 3, P < 
0.05).  (D,E) Exposure to SMase (20 min) generated endogenous long-chain ceramides 
from sarcolemmal sphingomyelins.  Most medium- and long-chain ceramides were 
significantly increased at the expense of the corresping chain-lengths of sphingomyelin (n 
= 6; *, P < 0.05).  Each lipid species was compared separately using a 3-way ANOVA 
based on two separate experimental data sets, each analyzed in triplicate.   
47 
 
 
 
current by 116 ± 16 % at + 60 mV (n = 5, P < 0.01).  Block of SMase-induced current by 
DCPIB and tamoxifen confirm its attribution to ICl,swell.  As expected, bacterial SMase 
increased myocyte ceramides and decreased sphingomyelins (Figure 5 D,E).  Tandem 
mass spectrometry demonstrated that SMase treatment significantly increased the 
concentrations of 8 of 11 ceramide chain-lengths examined, with C16-, C18:1-, C20:0-, 
and C22:0-ceramide demonstrating the most dramatic increases in total lipid normalized 
by cell protein.  The corresponding sphingomyelins showed the largest fraction 
decreases. 
The volume-sensitivity of Cl− current elicited by bacterial SMase was tested by 
exposure to hyperosmotic (1.5T) bathing solution in the continued presence of SMase 
(Figure 7).  Cell shrinkage under these conditions for 15 min inhibited SMase-induced 
current by 43 ± 8% (n = 6, P < 0.02), from 1.88 ± 0.20 to 1.41 ± 0.14 pA/pF at +60 mV 
(Figure 7B).  In contrast, we previously showed 1.5T fully suppresses ICl,swell elicited by 
upstream signaling molecules (Clemo et al., 1999).  SMase-induced current in 1.5T bath 
solution remained, however, significantly greater than control (n = 6, P < 0.02).  Partial 
inhibition by hyperosmotic cell shrinkage indicates that activation of SMase-induced 
current had both volume-sensitive and volume-independent components.  
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Figure 6:  Tamoxifen (Tam) inhibited SMase-induced ICl,swell.  (A) Families of currents 
before and after treatment with SMase (0.03 U/mL, 15 − 18 min) and then after addition 
of Tam (10 µM).  (B) I-V relationships.  (C) Tam fully blocks SMase-induced Cl− current 
(116 ± 16%, n = 5, P < 0.01).  Tamoxifen selectively blocks ICl,swell under conditions that 
isolate Cl− currents, confirming identification of SMase-induced current by DCPIB. 
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Figure 7:  Osmotic shrinkage partially inhibited SMase-induced ICl,swell.  (A) I-V 
relationships before (1T Ctrl) and after (1T+SMase) exposure to SMase (0.03 U/mL, 18 
min) in isosmotic bath solution, and then, after shrinking the same cell in hyperosmotic 
bath solution containing SMase (1.5T+SMase; 0.03 U/mL, 15 min).  (B) Current 
densities at +60 mV before and after treatment with SMase in 1T and 1.5T bath solutions.  
Cell shrinkage in 1.5T partially inhibited the SMase-induced Cl− current (43 ± 8%, n = 6, 
P < 0.02).  This suggested that SMase elicits ICl,swell via volume-dependent and volume-
independent pathways.   
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3.3.  Differences in time course of activation due to exogenous and endogenous 
ceramide  
Figure 8 compares the time course of activation of ICl,swell by C2-Cer and bacterial 
SMase.  The time course of C2-Cer-induced difference current was fit by a single 
exponential function with a time constant of 6.4 ± 1.6 min (R2 = 0.93, n = 11), equivalent 
to a t1/2 of 4.8 ± 1.2 min.  In contrast, SMase-induced difference current was fit by a 
sigmoid function with a t1/2 of 9.3 ± 0.6 min (R2 = 0.99, n = 10).  The magnitude of the 
current elicited at +60 mV by C2-Cer, bacterial SMase, and osmotic swelling (i.e., test − 
control) also were compared.  The C2-Cer-induced current (0.70 ± 0.09 pA/pF; n = 14) 
was significantly different than that evoked by bacterial SMase (1.01 ± 0.05 pA/pF; n = 
75, P < 0.02) or by hypoosmotic cell swelling in 0.7T bath solution (1.22 ± 0.17 pA/pF, 
data not shown; n = 6, P < 0.05), whereas the SMase- and swelling-induced currents 
were indistinguishable (P = 0.244). 
3.4. ROS mediate bacterial SMase-induced activation of ICl,swell  
Previously we demonstrated that H2O2 is a downstream mediator of ICl,swell 
activation and exogenous H2O2 elicits ICl,swell even under hyperosmotic conditions (Browe 
and Baumgarten, 2004; Ren et al., 2008).  As shown in Figure 9, ebselen (20 µM, 5 min), 
a cell-permeable glutathione peroxidase mimetic that converts H2O2 to H2O, inhibited the 
SMase-induced Cl− current by 124 ± 39% (n = 5, P < 0.01) from 2.46 ± 0.43 pA/pF to 
1.56 ± 0.33 pA/pF at +60 mV.  There was no difference in Cl− currents under control  
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Figure 8:  Time course of activation of ICl,swell by C2-Cer and bacterial SMase.  C2-
Cer data were fit by an exponential function with time constant of 6.4 ± 1.6 min (R2 = 
0.98, n = 11), equivalent to a t1/2 of 4.8 ± 1.2 min.  SMase data were fit by a sigmoid 
function with a t1/2 = 9.3 ± 0.6 min (R2 = 0.99, n =10).  Soluble C2-Cer may reach the site 
of activation of ICl,swell more quickly than long-chain endogenous ceramides that first 
must be produced by SMase.  Alternatively, ceramides with different chain lengths may 
activate different sites in the signaling cascade. 
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Figure 9:  The bacterial SMase-induced Cl− current was completely inhibited by 
ebselen.  (A) Families of currents before and after treatment with SMase (0.03 U/mL, 15 
− 18 min) and then after addition of ebselen (20 µM, 5 min).  (B) I-V relationships.  
(C) Ebselen, a glutathione peroxidase mimetic that scavenges H2O2, fully blocks SMase-
induced Cl− current, reducing the current density from 2.46 ± 0.43 pA/pF to 1.56 ± 0.33 
pA/pF at +60 mV.  These data suggest the SMase-induced Cl− current is mediated by 
H2O2, a downstream mediator of ICl,swell (Browe and Baumgarten, 2004; Ren et al., 2008). 
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conditions (1.59 ± 0.55 pA/pF) and after addition of ebselen (P < 0.87). This 
demonstrates that the SMase-induced Cl− current is mediated by ROS and is consistent 
with ICl,swell activation by exogenous H2O2. 
Once it was established that ROS, most likely H2O2, mediates SMase-induced 
ICl,swell activation, the next step was to determine the source of ROS in this process.  One 
of the primary sources of ROS generation in cardiomyocytes is the membrane-bound 
enzyme NOX.  It was previously demonstrated that inhibition of NOX abrogates 
hypoosmotic swelling- and β1 integrin stretch-induced ICl,swell (Browe and Baumgarten, 
2004; Ren et al., 2008).  As shown in Figure 10AB, the NOX inhibitor apocynin (500 
µM, 10 min) failed to inhibit SMase-induced ICl,swell activation (n = 9, P = 0.22 vs 
SMase).  Additionally, administration of the NOX-specific, membrane-permeant fusion 
peptide gp91ds-tat (500 nM, 10 min) also failed to inhibit ICl,swell that was activated by 
SMase (n = 4, P = 0.85 vs SMase) (Fig 10C).  By contrast, diphenyliodonium (DPI, 
60 µM, (20 – 25 min) fully inhibited SMase-induced current, from 2.01 ± 0.16 pA/pF to 
1.24 ± 0.20 pA/pF at +60 mV (n = 4, P = 0.71 vs control).  Previously, apocynin, gp91ds-
tat, and DPI where shown to inhibit NOX-dependent ICl,swell activation by osmotic 
swelling or β1 integrin stretch of ventricular myocytes within 5 min of administration.  
The failure of apocynin and gp91ds-tat to block SMase-induced current and the slow 
kinetics of block by DPI suggest that DPI may not be acting at NOX in this instance.   
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Figure 10:  Specific NOX inhibitors did not block SMase-induced ICl,swell.  (A) I-V 
relationships for Cl− current elicited by bacterial SMase (0.03 U/mL, 15-18 min) and after 
addition of apocynin (500 µM, 10 min) or DPI (60 µM, 20 – 25 min).  (B) Apocynin 
(Apo) failed to inhibit SMase-induced Cl− current while DPI abrogated Cl− current at +60 
mV.  (C) Gp91ds-tat (500 nM, 10 min), the cell-permeant fusion peptide inhibitor of 
NOX, also failed to inhibit bacterial SMase-induced activation of ICl,swell. 
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DPI is a flavoprotein inhibitor that suppresses NOX activity by dissociating an electron 
from NOX and forming a radical complex that covalently binds to and inhibits the NOX 
protein (O'Donnell et al., 1993).  DPI also inhibits other flavinoid compounds, including  
mitochondrial ETC Complex I (Lambert et al., 2008).  To test the idea that mitochondrial 
ROS production was responsible for SMase-induced ICl,swell, we used rotenone (10 µM, 
20 min), which inhibits the transfer of electrons from iron-sulfur centers of Complex I to 
ubiquinone (Degli-Esposti M., 1998) 
As seen in Figure 11, rotenone abrogated SMase-induced ICl,swell.  Exposure to 
SMase increased current from 1.17 ± 0.24 pA/pF to 2.22 ± 0.47 pA/pF, and addition of 
rotenone decreased the current to 1.06 ± 0.11 pA/pF (n = 5, P = 0.74 vs control).  Taken 
together, suppression of SMase-induced ICl,swell by rotenone and DPI is consistent with 
the idea that mitochondrial ROS generation is a required element of SMase-induced 
ICl,swell activation. 
Failure of apocynin and gp91ds-tat to inhibit ICl,swell that already was activated by 
SMase argues that ongoing production of ROS by NOX is not required to maintain 
current activation.  Alternatively, NOX might serve as trigger that is only transiently 
required to elicit mitochondrial ROS production.  Ceramide and other sphingolipids 
species are reported to stimulate NOX activity in vascular smooth muscle (Keller et al., 
2006; Won and Singh, 2006; Zhang et al., 2003), and there is evidence for crosstalk 
between NOX and mitochondria (Aon et al., 2003; Zorov et al., 2006). 
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Figure 11:  Block of mitochondrial ETC Complex I by rotenone completely inhibits 
SMase-induced ICl,swell.  (A) Families of currents before and after treatment with SMase 
(0.03 U/mL, 15 − 18 min) and then after addition of rotenone (10 µM, 20 min).  (B) I-V 
relationships.  (C) Rotenone, a specific inhibitor of Complex I of the mitochondrial ETC, 
fully blocks SMase-induced Cl− current, reducing the current density from 2.22 ± 0.47 
pA/pF to 1.06 ± 0.11 pA/pF (n = 5, P < 0.01).  These data suggest the mitochondrial ROS 
production is a required step in SMase-induced activation of ICl,swell. 
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Figure 12:  Pretreatment with gp91ds-tat reduced the magnitude of SMase-induced 
ICl,swell.  (A) Families of currents for cells pretreated with gp91ds-tat (Ctrl) and following 
addition of bacterial SMase (0.03 U/mL, 18 min).  (B) I-V relationships.  (C) SMase 
elicited ICl,swell in cardiomyocytes pretreated with gp91ds-tat (500 nM, 20 min).  
However, the magnitude of this activation was significantly smaller than that seen in non-
pretreated cells (0.60 ± 0.2 pA/pF, n =7 vs 1.01 ± 0.05 pA/pF, n = 75; P < 0.03).   
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In order to examine whether or not NOX might serve as a trigger, cardiomyocytes 
were pretreated with gp91ds-tat (500 nM) for 20 min prior to addition of SMase (0.03 
U/mL, 20 min) in the continued presence of gp91ds-tat.  As seen in Figure 12, SMase 
still elicited a significant increase in current, from 1.27 ± 0.16 pA/pF to 1.87 ± 0.34 
pA/pF at +60 mV (n = 7, P < 0.03).  However, the magnitude of SMase-induced current 
after pretreatment with gp91ds-tat shown here was significantly lower than that in the 
absence of gp91ds-tat (0.60 ± 0.20 pA/pF, n = 7 vs 1.01 ± 0.05 pA/pF, n = 75; P < 0.03).  
This suggests that while SMase-induced mitochondrial ROS production may be sufficient 
to maintain activation of ICl,swell, there may be crosstalk between NOX and mitochondria 
in the initiation of the process. 
3.5. Downstream metabolites of ceramide are involved in ICl,swell activation 
The addition of bacterial SMase converts sphingomyelins to ceramides and 
phosphocholine.  However, ceramides may be further modified to downstream 
metabolites, namely sphingosine and S1P, which are known to be potent signaling 
molecules (see Figure 1).  Our next step was to explore the possibility that such ceramide 
metabolites activate ICl,swell. 
Ceramide is converted to sphingosine through the action of ceramidases.  As 
shown in Figure 13, D-erythro-MAPP (10 µM, 15 – 18 min), a ceramide analogue that 
inhibits native ceramidase activity (Bielawska et al., 1996), fully blocked bacterial 
SMase-induced Cl− current.  SMase increased current from 0.62 ± 0.19 pA/pF to 1.45 ±  
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Figure 13:  D-erythro-MAPP (D-e-MAPP), a ceramidase inhibitor that blocks 
conversion of ceramide to sphingosine, completely inhibited SMase-induced Cl− 
current.  (A) Families of currents under control conditions (Ctrl), after treatment with 
bacterial SMase (0.03 U/mL, 18 min), and after addition of D-e-MAPP in the continued 
presence of SMase.  (B) I–V relationships for A.  (C) D-e-MAPP (10 µM, 15 – 18 min) 
abrogated bacterial SMase-induced Cl− current at +60 mV. SMase increased current from 
0.62 ± 0.19 pA/pF to 1.45 ± 0.42 pA/pF, and D-e-MAPP reduced it to 0.69 ± 0.25 pA/pF 
(n = 4, P < 0.01). 
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0.42 pA/pF and D-erythro-MAPP reduced it to 0.69 ± 0.25 pA/pF at +60 mV (n = 4, P < 
0.01), a 92 ±7 % block of the SMase-induced current.  There was no difference between 
control current density and that following treatment with D-erythro-MAPP (P = 0.70).  
This implies that sphingosine or its metabolites must be involved in the SMase-induced 
activation of ICl,swell.  
Sphingosine can be phosphorylated by sphingosine kinases to form the bioactive 
lipid S1P.  As seen in Figure 14, the sphingosine kinase inhibitor DL-threo-
dihydrosphginosine (10 µM, 15 – 20 min) fully inhibited bacterial SMase-induced ICl,swell.  
Exposure to SMase increased the current from 1.12 ± 0.14 pA/pF to 2.46 ± 0.36 pA/pF at 
+60 mV, and DL-threo-dihydrosphginosine reduced it to 1.35 ± 0.17 pA/pF at +60 mV (n 
= 6, P < 0.001) in the continued presence of SMase, a 82 ± 5% block.  There was no 
difference between control current density and that following treatment with DL-threo-
dihydrosphingosine (P = 0.31).  Taken together, these data implicate S1P as a modulator 
of ICl,swell.   
In order to verify that S1P is indeed responsible for ICl,swell activation in this 
system, our next step was to see if exogenous S1P would elicit ICl,swell.  S1P (500 nM, 10 
min) activated an outwardly-rectifying Cl− current with a reversal potential near ECl.  
Current at +60 mV increased from 0.92 ± 0.19 pA/pF to 2.11 ± 0.13 pA/pF (n = 4, P < 
0.02).  As seen in Figure 15, this current was fully inhibited by addition of DCPIB (10 
µM, 10 - 12 min) in the continued presence of S1P (n = 4, P = 0.67 vs control).  As found 
for the SMase-induced Cl− current, the activation of ICl,swell by S1P was completely  
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Figure 14:  DL-threo-dihydrosphingosine (DL-3-DHS), a sphingosine kinase 
inhibitor that blocks phosphorylation of sphingosine to S1P, completely inhibited 
SMase-induced Cl− current.  (A) Families of currents under control conditions (Ctrl), 
treatment with bacterial SMase (0.03 U/mL, 18 min), and following addition of DL-3-
DHS (10 µM, 15 – 20 min) in the continued presence of SMase.  (B) I–V relationships 
for A.  (C) Bacterial SMase increased current from 1.12 ± 0.14 pA/pF to 2.46 ± 0.36 
pA/pF. DL-3-DHS decreased current to 1.35 ± 0.17 pA/pF (n = 6; P <0.001 vs SMase, ns 
vs Ctrl). 
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Figure 15: Exogenous S1P elicited DCPIB-sensitive Cl− current.  (A) Families of 
currents under control conditions (Ctrl), after treatment with exogenous S1P (500 nM, 10 
min), and following addition of DCPIB (10 µM, 10 min) in the continued presence of 
S1P.  (B) I-V relationships for A.  (C) Exogenous S1P induced an outwardly-rectifying 
Cl− current that reversed near ECl and was fully attenuated by DCPIB (n = 4, P <0.02); 
current at +60 mV under control conditions was 0.88 ± 0.10 pA/pF, after exposure to S1P 
was 1.84 ± 0.16 pA/pF, and after addition of DCPIB was 0.96 ± 0.14 pA/pF.  
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inhibited by rotenone (10 µM, 15 – 20 min).  S1P increased current at +60 mV from 0.88 
± 0.1 pA/pF to 1.84 ± 0.16 pA/pF and rotenone reduced it to 0.96 ± 0.14 pA/pF (n = 7, P 
< 0.001) (Figure 16B).  This amounts to a 94 ± 9% block of the S1P-induced current.  
Interestingly, in contrast to SMase-induced ICl,swell, addition of apocynin (500 µM, 10 
min) in the continued presence of S1P partially reduced the S1P-induced Cl− current by 
56 ± 5%, from 1.64 ± 0.21 pA/pF to 1.23 ± 0.20 pA/pF at +60 mV (n = 4, P < 0.01) 
(Figure 16A). 
3.6. MAPK and mitoKATP channels are involved in SMase-induced ICl,swell 
activation  
Opening of mitoKATP channels is thought to modulate mitochondrial O2−• 
production by reducing the inner membrane potential gradient and thereby increasing 
ETC flux to intermediates that leak electrons to O2 (Hanley and Daut, 2005).  5-
hydroxydeconate (5-HD; 500 µM, 18 – 20 min), a mitoKATP channel antagonist, inhibited 
SMase-induced ICl,swell by 59 ± 5 % at +60 mV; current under control conditions was 0.77 
± 0.06 pA/pF, SMase increased current to 1.51 ± 0.18 pA/pF, and 5-HD reduced it to 
1.07 ± 0.11 pA/pF (n = 4, P < 0.01) (Figure 17).  Block of SMase-induced current by 5-
HD was not complete, however (P < 0.02 vs Ctrl).  These data implicate mitoKATP 
channel activation by SMase as an intermediate in the activation of ICl,swell.   
 MAPKs, specifically ERK 1/2, are involved in regulation of ICl,swell during heart 
failure (Clemo and Baumgarten, 1999) and sphingolipid-mediated signaling cascades  
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Figure 16:  S1P-induced Cl− current is partially inhibited by apocynin and fully 
inhibited by rotenone.  (A) I-V relationships for currents under control conditions (Ctrl), 
after treatment with S1P (500 nM, 10 min), and after addition of apocynin (+Apo; 500 
µM, 10 min) in continued presence of S1P.  (B) I-V relationships for block by rotenone 
(+Rot; 10 µM, 15-20 min); other conditions as in A.  (C) Apocynin inhibited 56 ± 5 % of 
S1P-induced ICl,swell (n =4, P < 0.01) and the remaining current was significantly greater 
than control (P < 0.01), whereas rotenone fully abolished the S1P-induced current (n = 7, 
P < 0.001). 
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Figure 17:  Block of mitoKATP channels partially inhibited SMase-induced ICl,swell.  
(A) I-V relationships for currents under control conditions (Ctrl), after treatment with 
bacterial SMase (0.03 U/mL, 15 - 18 min), and after addition of the mitoKATP blocker, 5-
HD (500 µM, 18 - 20 min) in continued presence of SMase.  (B) 5-HD inhibited SMase-
induced current by 59 ± 5 % (n = 4, P < 0.01 vs SMase, P < 0.02 vs Ctrl). 
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Figure 18:  ERK is involved in SMase-induced ICl,swell.  (A) I-V relationships for 
currents under control conditions (Ctrl), after treatment with bacterial SMase (0.03 U/mL, 
15 - 18 min), and after addition of the ERK1/2 blocker U0126 (5 µM, 15 min) in the 
continued presence of SMase.  (B) U0126 inhibited SMase-induced current by 66 ± 5 % 
(n = 4, P < 0.01 vs SMase, P < 0.02 vs Ctrl).  (C) The ERK1 blocker PD98059 inhibited 
SMase-induced current by 65 ± 8 % (n = 5, P < 0.01 vs SMase, P < 0.02 vs Ctrl). 
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(Maupas-Schwalm et al., 2004).  In order to determine the role of ERK in the signaling 
pathway that regulates SMase-induced ICl,swell, we examined the effects of ERK inhibitors 
on this current.  As illustrated in Figure 18AB, the ERK 1/2 blocker U0126 (5 µM, 15 
min) reduced SMase-induced Cl− current by 66 ± 5 %.  SMase increased current at +60 
mV from 0.82 ± 0.13 pA/pF to 1.64 ± 0.10 pA/pF, and U0126 in the continued presence 
of SMase reduced it to 1.13 ± 0.05 pA/pF (n = 4, P < 0.01).  Nevertheless, current after 
block by U0126 remained significantly greater than under control conditions (P < 0.02).  
The actions of the ERK 1-specific inhibitor PD98059 (10 µM, 15 min) were similar. 
PD98059 blocked 65 ± 8 % of the SMase-induced current at +60 mV; SMase increased 
the current from 1.19 ± 0.27 pA/pF to 1.95 ± 0.39 pA/pF and it was reduced to 1.44 ± 
0.30 pA/pF by PD08059 in the continued presence of SMase (n = 5, P < 0.01) (Figure 
18C).  Current after block by PD98059 remained significantly greater than that under 
control conditions (P < 0.02).  In contrast to the partial block of ICl,swell observed here 
with both U0126 and PD98059, the same concentrations of MAPK inhibitors previously 
were found to fully inhibit ICl,swell elicited by EGF (Deng and Baumgarten, 2009).  These 
data suggest that the activation of  ICl,swell by SMase involves both ERK-dependent and 
ERK-independent pathways. 
3.7  SMase-induced ROS production in HL-1 Cardiomyocytes 
The electrophysiological evidence presented so far suggested that ceramides 
activate ICl,swell by eliciting ROS production, but the evidence for ROS production is 
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indirect.  To more directly support this hypothesis, we measured ROS production with a 
fluorescent probe and flow cytometry.  These studies were undertaken in the HL-1 
cardiomyocytes cell line for technical reasons.  HL-1 cells are an immortalized murine 
atrial cell line that has been used to study the behavior of ion channels (Fox et al., 2005; 
Fukuda et al., 2005), mitochondria (Vassilopoulos and Papazafiri, 2005; Ruiz-Meana et 
al., 2006; Ruiz-Meana et al., 2003), and other physiologic and pathophysiologic 
properties (Claycomb et al., 1998) of cardiac myocytes.  Preparations of HL-1 cells are 
more uniform than freshly dissociated native cardiac myocytes, which unavoidably 
include damaged myocytes that may produce ROS.  Before undertaking the ROS 
measurements, it also was necessary to demonstrate that ceramides activated ICl,swell in 
HL-1 cells.  Unpublished data from the Baumgarten group indicate that ICl,swell is present 
in HL-1 cells at high current density and is regulated by several other signaling pathways 
previously characterized in native atrial and ventricular myocytes.   
We used bacterial SMase to determine whether ceramides activate a Cl– current in 
HL-1 cells.  As shown in Figure 19, bacterial SMase (0.03 U/mL, 15-18 min) elicited an 
outwardly-rectifying Cl− current with a reversal potential near ECl.  At +60 mV, Cl– was 
1.75 ± 0.35 pA/pF under control conditions and increased to 15.54 ± 5.17 pA/pF (n = 7, P 
< 0.01) after exposure to SMase.  The SMase-induced current was fully inhibited by 
addition of DCPIB (10 µM, 10 min) in the continued presence of bacterial SMase (n = 5, 
P < 0.01), and the current remaining after block by DCPIB was not significantly different 
than the control current (P = 0.58 vs Ctrl).  These data suggest that SMase evoked ICl,swell 
in HL-1 cardiomyocytes.    
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 The effect of bacterial SMase on ROS production in HL-1 cardiomyocytes was 
determined by flow cytometry using the fluorophore C-H2DCFDA-AM, which primarily 
detects  H2O2.  Figure 20 shows log fluorescence histograms from a single experiment.  
The geometric means of the histograms were normalized by background fluorescence, 
and summary data are depicted in Figure 21.  Measurements of ROS production were 
fully consistent with expectations based on the idea that ICl,swell is a ROS sensor.  
Bacterial SMase (10 µM, 40 min) significantly increased ROS production 4.4-fold 
(median) from the background levels.  This primarily was due to mitochondrial ROS 
production rather than NADPH oxidase.  Bacterial SMase-induced ROS production was 
suppressed to 1.52-fold (median) from background levels by pretreatment (30 min) with 
mitochondrial ETC blocker rotenone (10 µM) but was unaffected by pretreatment with 
the NADPH oxidase blocker gp91ds-tat (500 nM).  In comparison, fluorescence elicited 
by H2O2 (100 mM, 15 min) was increased 5.2-fold (median) above background (Figures  
20B & 21). Negligible responses were obtained from HL-1 myocytes in the absence of 
fluorophore (no drug) with or without addition of SMase (Figure 20A), indicating that 
neither the HL-1 myocytes nor the bacterial SMase itself contributed to the signal 
attributed to ROS. 
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Figure 19:  Bacterial SMase induced a DCPIB-sensitive Cl− current in HL-1 
cardiomyocytes.  (A) I-V relationships for currents under control conditions (Ctrl), after 
treatment with bacterial SMase (0.03 U/mL, 15 – 18 min), and after addition of DCPIB 
(10 µM, 10 min) in the continued presence of SMase.  (B) SMase induced an outwardly-
rectifying, DCPIB-sensitive Cl− current that reversed near ECl (n = 7, P <0.01).  Currents 
observed after addition of DCPIB were not statistically different from control (P = 0.59). 
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Figure 20:  Measurement of ROS with C-H2DCFDA-AM by flow cytometry of HL-1 
cells.  Typical log florescence (F) histograms from a single typical experiment.  (A) 
Negative controls in absence of florescent probe without (no drug) or with bacterial 
SMase (0.03 U/mL, 40 min).  (B) In fluorophore-loaded myocytes, background 
fluorescence (Ctrl) and response to H2O2 (100 µM, 15 min) and bacterial SMase (0.03 
U/mL, 40 min) reflect ROS production.  (C) Pretreatment with rotenone (Rot+SMase; 10 
µM, 40 min) suppressed ROS production to control levels.  Pretreatment with gp91ds-tat 
failed to appreciably reduce SMase-induced ROS.  Geometric means of F are shown in 
parenthesis. 
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Figure 21:  SMase activated ROS production via mitochondrial ROS in HL-1 
myocytes.  Geometric means of histograms normalized by background fluorescence 
(F/FO).  Bacterial SMase (0.03 U/mL µM, 30 min; n = 5, for each) significantly increased 
ROS production, which was suppressed by pretreatment with Rot (10 µM, 40 min; n = 4) 
but not by pretreatment with gp91ds-tat (500 nM, 40 min; n = 4).  H2O2 (100 µM, 15 
min; n = 4) was positive control.  Data were analyzed by Kruskal-Wallis One Way 
Analysis of Variance on Rank compared to control florescence by Dunn’s Method.  Box 
plots show 25, 50 and 75 percentile; dotted line, background florescence.   
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Chapter 4 
DISCUSSION 
 
This study demonstrated for the first time that both exogenous C2-Cer, a 
membrane-permeant short chain ceramide, and endogenous, long-chain ceramides 
generated by bacterial SMase activated a Cl− current with the biophysical and 
pharmacological properties of ICl,swell in rabbit ventricular myocytes.  Furthermore, 
endogenous ceramides generated by bacterial SMase appear to act by eliciting the 
production of S1P, and exogenous S1P also elicited a Cl− current with features of ICl,swell.  
The slow time course of current activation by these sphingolipids, the involvement of 
ROS, and suppression of ICl,swell by inhibitors of ceramide metabolism suggests the 
participation of a signaling cascade rather than direct interaction of all of these 
sphingolipids with the channel. 
4.1. Characteristics of ceramide-induced Cl− current 
The primary Cl− channels present in heart are ICl,swell, the cystic fibrosis 
transmembrane conductance regulator (CFTR) Cl− channel, and Ca2+-activated Cl− 
channels (ICl,Ca)  (Hume et al., 2000).  C2-Cer- and bacterial SMase-induced currents 
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reversed near ECl, exhibited outward rectification in physiological and symmetrical Cl− 
gradients, and were partially inhibited by hyperosmotic cell shrinkage.  These features 
closely matched those of ICl,swell described previously (Baumgarten et al., 2005; Hume et 
al., 2000; Sorota, 1994; Tseng, 1992).  Additionally, the block of C2-Cer- and SMase-
induced Cl− current by selective blockers, DCPIB and tamoxifen, strongly implicated 
ICl,swell.  ICl,Ca and ICFTR are insensitive to block by DCPIB (Decher et al., 2001), and 
tamoxifen selectively inhibits ICl,swell, and not the outwardly-rectifying ICFTR, under 
conditions that isolate anion currents (Vandenberg et al., 1994).  It is unclear why DCPIB 
gave apparently incomplete inhibition (76 ± 8%) whereas tamoxifen completely 
abrogated the current.  In contrast, 10-µM DCPIB fully inhibits ICl,swell elicited by 
hypoosmotic cell swelling in cardiomyocytes (Decher et al., 2001).  Because the 
molecular identity of ICl,swell remains elusive, the mechanisms of ICl,swell inhibition by 
these two agents is not well-understood, and they may act at different sites.  ROS have 
been shown to activate ICl,swell (Varela et al., 2004; Shimizu et al., 2004; Ren et al., 2008; 
Haskew-Layton et al., 2005; Browe and Baumgarten, 2006; Browe and Baumgarten, 
2004).  Tamoxifen may suppress ICl,swell by acting as a ROS scavenger and by inhibiting 
Complex I of the mitochondria electron transport chain (Moreira et al., 2006), preventing 
ROS from spilling over into the cytoplasm.  No information is available on the 
mechanism of block of ICl,swell by DCPIB, an ethacrynic acid derivative. 
Effects of sphingolipids on sarcolemmal channel function have been explored 
only recently.  Prolonged (>10 h) C2-Cer and bacterial SMase exposure down regulates 
HERG K+ channels through a pathway involving ROS production (Chapman et al., 2005; 
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Bai et al., 2007), and CFTR Cl− current is inhibited by both more rapidly (<60 min) (Ito 
et al., 2004).  These effects appear to be PKA- and PKC-independent.  d'Anglemont de 
Tassigny et al. (2004) found that ICl,swell is a required participant of the apoptotic volume 
decrease in cardiomyocytes and hypothesized that ICl,swell is activated in C2-Cer-induced 
apoptosis.  Although outwardly rectifying Cl− currents were observed during 
doxorubicin-induced apoptosis, these authors − in contrast to the present study − did not 
establish a link between ceramide and ICl,swell activation.  
Modification of direct interactions between membrane lipids and channel proteins 
has been invoked to explain altered gating of KV channels (Ramu et al., 2006; Milescu et 
al., 2007) and inhibition of CFTR (Ramu et al., 2007) after treatment with SMase D.  
SMase D is distinct from bacterial SMase (SMase C) and depletes membrane 
sphingomyelin without stimulating ceramide signaling; hydrolysis of sphingomyelin by 
SMase D is at the opposite side of the phosphate group, producing choline and ceramide-
1-phosphate rather than the phosphocholine and ceramide generated by bacterial SMase.  
Such depletion of membrane lipids is not likely to explain the present results, however.  
C2-Cer and bacterial SMase both activated ICl,swell, whereas C2-Cer will favor, if anything, 
an increase in sphingolipids rather than their depletion.  Nevertheless, a contribution of 
lipid-protein interactions to the response observed here cannot be rigorously excluded.  
Swelling in 0.7T gives nearly full activation of ICl,swell in ventricular myocytes 
(Clemo et al., 1999), and the magnitude of the current elicited by bacterial SMase and 
hypoosmotic swelling were not distinguishable.  In contrast, C2-Cer evoked a 
significantly smaller current (~70% of SMase- and 60% of 0.7T-induced currents) that 
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activated more rapidly, and increasing C2-Cer from 2 to 20 µM did not elicit additional 
current.  These differences may reflect, in part, that C2-Cer must permeate the 
sarcolemma to reach its target(s) and that SMase first must hydrolyze sarcolemmal 
sphingomyelin to native long-chain ceramides, which also must reach their downstream 
target(s).  The Hill coefficient of the dose-response relationship for C2-Cer-induced 
ICl,swell is greater than one, suggesting cooperativity and that the effect of C2-Cer is likely 
to be due to induction and amplification of a signaling cascade rather than direct one-to-
one ligand binding.  It also is possible that synthetic short-chain and native long-chain 
ceramides work via distinct pathways or differ in their efficacy to stimulate processes 
causing ICl,swell activation.  Our observation that hyperosmotic cell shrinkage in 1.5T only 
partially inhibits SMase-induced current may suggest that endogenous long-chain 
ceramides act at multiple sites and that one is downstream from the site controlled by 
hyperosmotic shrinkage.  Insensitivity of ICl,swell to osmotic shrinkage when the current is 
elicited by a downstream effector is not unique.  We previously showed that H2O2-
induced ICl,swell is insensitive to hyperosmotic shrinkage in 1.5T bathing solution (Ren et 
al., 2008). 
The lack of an effect of metabolically inactive C2-H2Cer lends support to the 
hypothesis that both C2-Cer and endogenous ceramides generated by bacterial SMase act 
via one or more ceramide signaling cascades rather than through a non-specific 
mechanism (Bielawska et al., 1993)  Furthermore, the slow time course of ICl,swell 
activation by C2-Cer and SMase is consistent with a process that involves signaling rather 
78 
 
 
than direct activation due to interaction with a binding site on the outer face of the 
channel.   
4.2 ROS are Required for Bacterial SMase-induced Activation of ICl,swell 
In cardiomyocytes, ROS produced by NADPH oxidase (Browe and Baumgarten, 
2004; Browe and Baumgarten, 2006; Ren et al., 2008) and mitochondria (Browe and 
Baumgarten, 2005) are essential downstream effectors of ICl,swell activation by osmotic 
swelling, integrin stretch, and growth factors, and ROS elicits ICl,swell in other tissues 
(Varela et al., 2004; Shimizu et al., 2004).  Ceramides also produce ROS.  For example, 
apoptosis triggered by ceramide is accompanied by mitochondrial ROS production 
(Feuerstein and Young, 2000; Hannun, 1996; Levade et al., 2001).  Regulation of ROS 
production by mitochondria is complex, however.  Mitochondria can be both the source 
and target of ROS, and ROS can have either pro- or anti-apoptotic effects.  Additionally, 
ceramide is involved in NADPH oxidase activation in rat mesangial and bovine coronary 
artery smooth muscle cells (Yi et al., 2004; Zhang et al., 2003). 
H2O2 is a membrane permeant, relatively long-lived ROS that interacts with 
several signaling molecules and ion channels (Lambeth, 2004).  Exogenous H2O2 elicits 
ICl,swell in rabbit ventricular myocytes (Browe and Baumgarten, 2004; Ren et al., 2008), 
HeLa cells (Varela et al., 2004), and rat hepatoma cells (Shimizu et al., 2004).  
Dismutation of H2O2 with catalase inhibits activation of ICl,swell induced by intergrin 
stretch and osmotic swelling (Browe and Baumgarten, 2004; Ren et al., 2008).  
Consistent with these observations, bacterial SMase-induced ICl,swell activation was 
completely inhibited by the glutathione peroxidase mimetic ebselen.  Combined with 
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previous evidence that ICl,swell is activated by exogenous H2O2, this suggests that SMase-
induced ICl,swell is mediated by H2O2 and its signaling intermediates.  However, as ebselen 
also reacts with peroxynitrite and phospholipid and cholesterol ester hydroperoxidases 
(Schewe, 1995), we cannot exclude that other ROS may be involved. 
The mechanism of H2O2-mediated regulation of ICl,swell remains unknown.  
Evidence suggests that that H2O2 must act a site distal to the volume-sensing mechanism 
as H2O2-indudced ICl,swell activation is not reversed by hyperosmotic cell shrinkage (Ren 
et al., 2008).  It is possible that direct modification of the channel by ROS modulates the 
properties of ICl,swell.  Although the molecular identity of ICl,swell is unknown, H2O2 has 
been shown to directly modify other cardiac ion channels as well as the redox-sensitive 
signaling cascades that regulate them (Zima and Blatter, 2006).  Such redox-sensitive 
signaling cascades have recently been implicated in modulation of ICl,swell in rat hepatoma 
cells through the activation of PLCγ1 and subsequent Ca2+ mobilization (Varela et al., 
2007).  A Ca2+-dependent mechanism for ICl,swell activation by H2O2 is difficult to 
reconcile with our observation in cardiac myocytes that ICl,swell is observed in Ca2+-free 
bath containing EGTA.  In fact, Varela et al. (2007) demonstrated that while H2O2-
induced current was suppressed with IP3 receptor and generic PLC inhibition, reduction 
of free Ca2+ did not alter the magnitude of ICl,swell in their system.  Other studies support 
the idea that an increase of Ca2+ is not required to activate ICl,swell.  For example, release 
of Ca2+ by store-operated calcium channels actually inhibits ICl,swell (Zholos et al., 2005; 
Lemonnier et al., 2002). 
4.3 Bacterial SMase Activates ICl,swell via ROS from Mitochondria but not NOX 
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As mentioned previously, ROS produced by both NOX and mitochondria are 
essential mediators of ICl,swell activation in cardiomyocytes by several stimuli (Browe and 
Baumgarten, 2004; Browe and Baumgarten, 2006; Browe and Baumgarten, 2007; Deng 
et al., 2009; Ren et al., 2008).  NOX transfers electrons from intracellular NADPH to 
form extracellular O2−•, which in turn is rapidly dismutated to H2O2 spontaneously or via 
extracellular superoxide dismutase (Bedard and Krause, 2007).  Previous studies from 
our laboratory showed that blockade of NOX inhibits ICl,swell activation induced by Ang 
II, ET-1, EGF, integrin stretch, and osmotic swelling.  Sphingolipids have also been 
implicated as mediators of NOX.  Ceramide increases the levels of GTP-bound Rac, thus 
stimulating translocation of the cytosolic components of NOX to the plasma membrane in 
mesangial cells (Yi et al., 2004).  Additionally, CD95L-induced p47phox phosphorylation 
in hepatocytes is sensitive to blockade of SMase (Reinehr et al., 2005) and ceramide 
induced NOX activation in small coronary arteries is associated with translocation of 
p47phox to the plasma membrane (Zhang et al., 2003).  Exogenous C2-Cer also increases 
NOX activity in bovine coronary arteries (Zhang et al., 2003).   
However, in the present study we found that bacterial SMase-induced ICl,swell 
activation was insensitive to block of NOX with either apocynin or gp91ds-tat.  
Interestingly, pretreatment of ventricular cardiomyocytes with gp91ds-tat modestly 
decreased the magnitude of SMase-induced activation of ICl,swell (Figure 12).  This may 
indicate that SMase induces ROS production via NOX acts as a trigger, but that this 
source of ROS is not required to maintain ICl,swell in its activated state.  Apocynin prevents 
the migration of p47phox to the plasma membrane, whereas the fusion peptide gp91ds-tat 
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blocks the p47phox docking site on the cytoplasmic complex of NOX (Bedard and Krause, 
2007).  Both are intended to inhibit NOX2, as this is the primary isotype of NOX found 
in the heart; they should  not inhibit NOX4 because p47phox is not a component of NOX4, 
an isoform that is constitutively active rather than being regulated by assembly of a 
cytoplasmic complex (Byrne et al., 2003a).  Nevertheless, we cannot rigorously exclude 
the possibility that bacterial SMase is leading to ROS production through the activation 
of the low concentration NOX4 that is present.   
Preliminary data indicate that mitochondrial ROS production is involved in the 
regulation of ICl,swell by ACh and HIV protease inhibitors in cardiomyocytes (Browe and 
Baumgarten, 2007; Deng et al., 2009).  Ceramide also induces mitochondrial ROS 
production in cardiomyocytes and other cell types (Di Paola M. et al., 2000; Garcia-Ruiz 
et al., 1997b; Gudz et al., 1997).  Mitochondrial ETC Complexes I and III are the primary 
redox centers responsible for electron leak and O2−• generation in mitochondria (Chen et 
al., 2008; Vanden Hoek et al., 1998).  O2−• generated by Complex I is released into the 
mitochondrial matrix and degraded by the matrix anti-oxidant system, which includes 
Mn2+-dependent SOD, catalase, and glutathione peroxidase (Chen et al., 2008; Chen et 
al., 2007).  By contrast, Complex III releases O2−• on both sides of the inner 
mitochondrial membrane and plays a central role in cytoplasmic ROS generation by 
mitochondria (Muller et al., 2004).  The role of mitochondrial ROS in the activation of 
ICl,swell by bacterial SMase was supported by the observation that selective inhibition of 
Complex I with rotenone, abrogated ICl,swell.  Block of Complex I at a distal binding site 
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by rotenone will abolish electron transport to and O2−• production by Complex III, 
whereas, if anything, it will favor O2−• production by Complex I.   
Although inhibitors of ROS production by mitochondria and NADPH oxidase and 
H2O2 scavengers, such as ebselen, are widely used tools with well-understood actions, the 
electrophysiological evidence supporting the role of ROS in ICl,swell activation is 
inherently indirect because ROS are not measured.  In contrast, flow cytometry of HL-1 
cardiac myocytes that were loaded with C-H2DCFDA-AM, a fluorophore that detects 
H2O2, provided direct support for this idea.  Pretreatment with rotenone largely prevented 
SMase-induced ROS production in HL-1 cardiomyocytes, whereas pretreatment with 
gp91ds-tat had no effect on SMase-induced ROS production in HL-1 cells (Figures 20-
21).  These fluorescence data support the conclusion drawn from electrophysiological 
data showing activation of ICl,swell was reversed on suppressing mitochondrial ROS 
production but was not reversed on suppressing ROS produced by NADPH oxidase 
(Figures 10-11).   
At first glance, however, one aspect of the data appears inconsistent: pretreatment 
of native ventricular myocytes with gp91ds-tat slightly reduced the magnitude of SMase-
induced ICl,swell activation (Figure 12).  As noted above, this raised the possibility that 
NOX ROS production can act as a trigger or modulator that speeds mitochondrial ROS 
production and the activation of ICl,swell.  The flow cytometry data also suggested 
mitochondrial production was not the only source of ROS stimulated SMase.  Although 
rotenone significantly suppressed ROS production, it remained at a level significantly 
higher than control (Figures 20-21).  It also must be recognized that a 1:1 correspondence 
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between flow cytometry and electrophysiological estimates of ROS production is not 
expected.  Variations in the relationship may arise from kinetics, localization, and 
sensitivity to ROS production.  Because scavenging ROS suppresses ICl,swell after its 
activation, ICl,swell must reflect ROS production throughout its period of activation, 
although the amount of ROS needed to fully activate current is unknown and the 
relationship is likely to be non-linear and perhaps time dependent.  Moreover, because 
ROS are highly reactive, the ROS that activates ICl,swell must be spatially localized.  In 
contrast, ROS is detected in flow cytometry studies by converting a non-fluorescent 
molecule to one that is fluorescent.  Fluorophores integrate ROS production over time, 
and therefore, a pretreatment paradigm must be used to study interventions that suppress 
ROS production.  Flow cytometry will detect ROS from all cellular sources, even those 
distant from ICl,swell such as interfibrillar mitochondria.  Finally, the maximum 
fluorescence depends upon the amount of non-fluorescent probe trapped in the cell.  The 
observation that SMase increased fluorescence to a level indistinguishable from that 
observed with 100-µM H2O2 might imply that all of the probe was converted to its 
fluorescent form by both interventions.  In such a situation, SMase-induced fluorescence 
might not be reduced even if ROS production was partially inhibited by gp91ds-tat.
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  4.4 Ceramide Metabolites are Required for SMase-induced ICl,swell Activation 
An important aspect of sphingolipid signaling is the ceramide/S1P rheostat 
(Hannun and Obeid, 2008).  Ceramide and its metabolite, S1P, are potent bioactive lipids 
that act as second messengers, often with opposing effects on signaling and ultimately the 
fate of the cell.  Ceramide tends to activate pathways leading to apoptosis, senescence, 
and differentiation.  By contrast, S1P is involved in proliferation, mitogenesis, migration, 
and tends to inhibit apoptosis (Hannun, 1994; Hannun and Obeid, 2008).  This raises the 
possibility that the relative ratio of these sphingolipids, rather than their concentrations, 
may be critical for controlling ICl,swell.  Ceramide and S1P are involved in modulation of 
cytosolic ROS generation due to a number of stimuli, including TNFα, 
ischemia/reperfusion, and changes in transmural pressure (Di Paola M. et al., 2000; 
Garcia-Ruiz et al., 1997b; Ide et al., 2001; Keller et al., 2006) and may also modulate 
ICl,swell, at least in part, by this pathway.   
Despite the fact that ceramide and S1P often have opposing actions, S1P appears 
to have paradoxical roles in some systems.  S1P has both anti- and pro-atherogenic 
properties (Chatterjee, 1998; Chatterjee et al., 2006; Murata et al., 2000; Xu et al., 2004).  
Additionally, both ceramide and S1P both increase ROS production in cardiomyocytes, 
vascular smooth muscle cells, and other tissues (Lecour et al., 2006b; Suematsu et al., 
2003; Takuwa et al., 2009; Zhang et al., 2003).  Exogenous S1P stimulates H2O2-
production in thyroid cells, although the source of this ROS was not investigated 
(Okajima et al., 1997).  Increased transmural pressure induces SPHK1 activity and 
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subsequent ROS generation in vascular smooth muscle cells, at least in part due to 
activation of NOX (Keller et al., 2006).   
Consistent with a role for ROS, we observed that exogenous S1P activates ICl,swell 
in ventricular cardiomyocytes.  S1P-induced activation of ICl,swell was fully blocked by 
rotenone and partially suppressed by apocynin, implicating both mitochondria and NOX, 
as discussed above for SMase.  Moreover, SMase-induced activation of ICl,swell is also 
dependent on endogenous generation of S1P.  Both inhibition of ceramidase with D-
erythro-MAPP and SPHK with DL-threo-dihydrosphingosine abrogated SMase-induced 
ICl,swell.  D-erythro-MAPP prevents the hydrolysis of the acyl chains of ceramide leading 
to an increase in ceramide and depletion of sphingosine and S1P.  Therefore, block of 
SMase-induced ICl,swell by D-erythro-MAPP indicates that a SMase-induced increase in 
the concentration of native ceramides cannot be the primary effector of ICl,swell.  
Moreover, inhibition of SPHK specifically depletes cells of S1P.  Together these data 
strongly argue that S1P rather than native ceramide is the essential signaling element in 
SMase-induced activation of ICl,swell.   
As mentioned previously, there are two primary isotypes of SPHK with different 
kinetic properties, cellular locations, and temporal expression (Spiegel and Milstien, 
2002).  Recent evidence suggests that SPHK1 and SPHK2 have antagonizing effects in 
the regulation of ceramide biosynthesis and mitochondrial Ca2+ (Maceyka et al., 2005).  
Whereas DL-threo-dihydrosphingosine is a potent inhibitor of overall SPHK activity 
(Buehrer and Bell, 1992), the isotype specificity of this blocker is unknown.  Recently, 
SPHK isotype-specific inhibitors have been identified (Takabe et al., 2008); these agents 
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may represent important pharmacological tools for determining the role of differential 
activation of SPHK isoforms in ROS generation and ICl,swell activation.  It remains unclear 
whether exogenous S1P-induced activation of ICl,swell depends on intracellular S1P 
binding sites or involves  G protein-coupled receptors that recognize S1P as a ligand 
(Maceyka et al., 2005; Means and Brown, 2009).  Bacterial SMase-induced S1P 
production likely makes use of endogenous sphingolipid trafficking mechanisms, 
whereas exogenous S1P may act at additional sites.  This may explain the discrepancy 
that SMase-induced ICl,swell is insensitive to NOX inhibition while exogenous S1P-
induced ICl,swell is partially inhibited by NOX block. 
 There are five members of this family, termed S1P1-5.  These subtypes are 
differentially expressed in various tissues and may be differentially expressed in distinct 
cellular compartments.  S1P1 is the primary subtype expressed in cardiomyocytes, but 
S1P3 and S1P2 are also present at lowever levels (Means and Brown, 2009).  S1P1 
receptor activation stimulates ERK, eNOS, Rac, PLC, and PI-3K signaling pathways and 
their affinity for S1P is augmented by H2O2 (Takabe et al., 2008; Igarashi et al., 2007).  
Exogenous H2O2 also increases S1P1 receptor expression (Igarashi et al., 2007).  This 
may identify a potential node for crosstalk between S1P receptors and ROS in 
cardiovascular responses.  Moreover, S1P receptors may serve as a potential feedback 
mechanism for regulating intracellular ROS.  Although the current study does not address 
the role of specific S1P receptors in activation of ICl,swell, it is a fertile area for future 
investigation.   
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4.5 ERK and mitoKATP Channels are Involved in SMase-induced ICl,swell 
ERK signaling is important in cardiac hypertrophy and cardioprotection (Muslin, 
2008; Heineke and Molkentin, 2006) and is activated by mechanical stretch (Caldiz et al., 
2007), Ang II (Ruf et al., 2002; Fischer et al., 1998), EGF (Kodama et al., 2002), and 
H2O2 (Duquesnes et al., 2009; Fukuzawa et al., 2002).  In the context of sphingolipid 
signaling, ceramide primarily actives the JNK cascade of MAPKs, whereas S1P activates 
the ERK pathway (Spiegel and Milstien, 2002; Hannun and Obeid, 2008).  ICl,swell elicited 
by EGF and ET-2 is fully inhibited by ERK blockade (Du and Sorota, 2000). By contrast, 
both the ERK1/2 blocker PD98059 and the ERK 1 blocker U0126 only partially inhibit 
bacterial SMase-induced ICl,swell.  This indicates that SMase activates ICl,swell via a 
complex mechanism with both ERK-dependent and ERK-independent components.  The 
partial dependence of bacterial SMase-induced ICl,swell on ERK activation is consistent 
with the observation that S1P is a required intermediate in this pathway.  The regulation 
of ICl,swell by ERK is complicated and, as the molecular identity of the channel responsible 
for ICl,swell is unknown, it is unclear if ERK acts via direct phosphorylation of channel 
residues or by activating other signaling molecules involved in regulating ICl,swell. 
The regulation of ICl,swell has recently been tied to the activation of mitoKATP 
channels.  Mitochondrial ROS production is stimulated by opening of mitoKATP channels 
(Andrukhiv et al., 2006).  Additionally, glibenclamide, a blocker of mitochondrial and 
sarcolemmal KATP channels, inhibits cardiac ICl,swell (Yamazaki and Hume, 1997; 
Sakaguchi et al., 1997) and blockade of mitoKATP channels with 5-HD abrogates ICl,swell 
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elicited by ACh (Browe and Baumgarten, 2007).  Sphingolipids have also been 
implicated in the regulation of KATP channels.  The glycosphingolipid C16:0 sulfatide 
reduces the sensitivity of mitochondrial KATP channels to ATP inhibition, leading to 
increased channel activity in rat pancreatic β cells (Buschard et al., 2006).  In the present 
study, bacterial SMase-induced ICl,swell was partially inhibited by 5-HD.  Although this is 
generally accepted as strong evidence of involvement of mitoKATP channels, there are 
certain alternatives that must be considered (Ardehali and O'Rourke, 2005; Hanley and 
Daut, 2005).  5-HD is a substituted medium-chain fatty acid that is metabolized by acyl-
CoA synthase.  5-HD-CoA or one of its metabolites may interfere with β-oxidation of 
fatty acids and disturb mitochondrial metabolism (Ardehali and O'Rourke, 2005; Hanley 
and Daut, 2005).  ICl,swell was elicited in pipette solution which contained ATP and Cs+ 
replacing K+ and lacked substrate.  While Cs+ is a known sarcolemmal KATP channel 
blocker, it does not block mitoKATP channels (Mironova et al., 1997).  In view of these 
issues, we cannot rigorously exclude the possibility that inhibition of SMase-induced 
ICl,swell by 5-HD is independent of its ability to block mitoKATP channels. 
4.6 Proposed Mechanism for Sphingolipid-induced ICl,swell Activation 
A proposed model that accounts for both our present and previous studies is 
shown in Figure 22.  Pretreatment with gp91ds-tat reduced maximum current elicited 
with SMase while apocynin and gp91ds-tat failed to inhibit current following SMase-
induced activation of ICl,swell.  The superoxide produced by NOX rapidly undergoes 
dimutation to H2O2, which is a distal mediator of ICl,swell activation in response to a 
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number of stimuli (Browe and Baumgarten, 2004; Browe and Baumgarten, 2006; Ren et 
al., 2008).  Consistent with previous observations, SMase-induced ICl,swell was abolished 
by membrane-permeant glutathione peroxidase mimetic ebselen.  Low levels of ROS 
produced by NOX might induce additional ROS production by mitochondria, a process 
of signal amplification.  In agreement with this scheme, ICl,swell evoked by bacterial 
SMase and exogenous S1P was abrogated by selective blockade of mitochondrial ROS 
production.  Moreover, ERK inhibitors U0126 and PD98059 partially inhibit SMase-
induced ICl,swell, as does hyperosmotic shrinkage.  This indicates that sphingolipid 
activation is occurring through at least two parallel pathways.   
In Figure 22, we outline the proposed mechanism of sphingolipid activation of 
ICl,swell.  Exogenous bacterial SMase converts sphingomyelin in the plasma membrane to 
ceramide.  Ceramide is then hydrolyzed by ceramidase to form sphingosine which in turn 
is phosphorylated by sphingosine kinase to form S1P.  S1P is downstream of ceramide in 
the activation of ICl,swell as block of ceramidase with D-erythro-MAPP and sphingosine 
kinase with DL-threo-dihydrosphingosine completely inhibits SMase-induced current.  
S1P leads to the production of ROS, a downstream mediator of ICl,swell, evidenced by the 
complete block of SMase-induced ICl,swell with the glutathione peroxidase mimetic 
ebselen.   
Exogenous S1P acts through at least two parallel pathways that converge at the 
level of the mitochondria to produce ROS and activate ICl,swell.  SMase-induced ICl,swell is  
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Figure 22:  Proposed mechanism of sphingolipid induced activation of ICl,swell.  
Bacterial SMase activates ICl,swell through S1P-dependent ROS generation.  Both 
endogenous and exogenous S1P stimulate mitochondrial ROS production through an 
unknown mechanism.  Exogenous S1P stimulates both NOX and mitochondria; either 
directly or through interaction with G protein coupled S1P receptors.  Exogenous C2-Cer, 
but not C2-H2Cer, also interacts with both NOX and mitochondrial ETC at the level of 
Complex III.  Scavenging of ROS abrogates SMase-induced ICl,swell, indicating ROS are a 
downstream effector of ICl,swell in this system.  Solid arrows indicate stimulatory 
pathways.  Dotted lines indicate potential pathways.  Red indicates inhibition and X 
indicates no action. 
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completely blocked by the Complex I inhibitor rotenone, as is S1P-induced ICl,swell.  
Exogenous S1P is also partially inhibited by apocynin, indicating at least part of the S1P-
induced ROS production is due to stimulation of NOX.  It is unclear, however, if this is a 
direct effect of S1P or is mediated through S1P receptors in the sarcolemmal membrane.  
Exogenous C2-Cer, but not the inactive analogue C2-H2Cer, also activates ICl,swell.  
Previous studies implicate NOX (Zhang et al., 2003) and mitochondrial Complex III 
(Gudz et al., 1997) as sources of C2-Cer-induced ROS production. Although the source of 
ROS was not verified, it is likely that C2-Cer induces ROS generation via both 
mechanisms in a similar manner to that seen with exogenous S1P.   
4.7 Implications 
ICl,swell is persistently activated in models of dilated cardiomyopathy (Baumgarten 
et al., 2005) and is involved in the apoptotic volume decrease (AVD) (Rasola et al., 1999; 
Okada and Maeno, 2001) that precedes apoptotic cell death in normal development, 
ischemia, or heart failure.  The sphingomyelin/ceramide pathway is activated in vivo 
during ischemia/reperfusion (Bielawska et al., 1997; Chatterjee et al., 2006; Gulbins and 
Li, 2006) and heart failure (Gulbins and Li, 2006; Doehner et al., 2007; Chatterjee et al., 
2006), and the oxidation of sphingolipids is implicated in atherosclerotic plaque 
formation (Auge et al., 2000).  The data presented here shows a link between intracardiac 
ceramide accumulation and ICl,swell activation that may be important for understanding 
these cardiovascular disease states.  Because ICl,swell outwardly rectifies, its activation 
promotes shortening of action potential duration (APD) and tends to depolarize resting 
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membrane potential, Em.  This may be beneficial in heart failure, where the APD is 
prolonged due to downregulation of repolarizing K+ currents.  On the other hand, 
decreasing APD reduces the minimum length of the conduction pathway needed to 
sustain re-entrant tachyarrhythmias and could be a contributor to the development of 
fibrillation. 
4.8. Future Directions  
There are a number of directions that warrant further study to provide a greater 
understanding of sphingolipid regulation of ICl,swell through ROS production.  Ang II and 
the acute activation of AT1 receptors are involved in activation of ICl,swell induced by 
integrin stretch and osmotic swelling (Browe and Baumgarten, 2004).  Ang II has also 
been implicated in modulation of ceramide production in vascular smooth muscle cells 
primarily through the action of AT2 receptors (Berry et al., 2001).  In this study ceramide 
accumulation was seen after long periods (1 – 10 h) of exposure to Ang II (Berry et al., 
2001).  In contrast, we have preliminary evidence that short (10 min) exposure to 5 nM 
Ang II alters the sphingolipid profile of ventricular cardiomyocytes (Figure 23).  At this 
concentration and treatment duration, Ang II activates ICl,swell (Ren et al., 2008).  Because 
of the central role of Ang II in cardiovascular disease, the potential role of sphingolipid 
signaling in Ang II-induced ICl,swell activation is worth investigating. 
Sphingolipids are important mediators of apoptosis and have been implicated in 
initiation of mitochondrial permeability transition pore (mitoPTP) formation, a vital step 
in the progression of apoptosis (Hannun and Obeid, 2008; Hannun, 1996).  Although the 
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Figure 23:  Preliminary tandem mass spectrometry data indicate Ang II induced 
alterations in sphingolipid metabolism.  (A) Most medium- and long-chain 
sphingomyelins were significantly increased in response to 10 min exposure to Ang II 
(10 nM) (n = 3; *, P < 0.05). (B) No significant change was detected in ceramide levels.  
Signal strength was not sufficient to detect S1P levels in these experiments.  Each lipid 
species was compared separately using a 3-way ANOVA based an single experimental 
data set, analyzed in triplicate.   
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mechanism is not fully understood, ceramide and sphingosine form large conductance 
channels in the mitochondrial outer membrane that have been postulated to contribute to 
mitoPTP opening (Siskind et al., 2002; Siskind et al., 2006).  ICl,swell is also implicated in 
apoptosis and is necessary for the AVD (Okada et al., 2009; d'Anglemont de Tassigny et 
al., 2004).  As mitoPTP opening would increase ROS permeability of the mitochondrial 
membranes by forming a ROS-permeant pathway bridging the inner and outer 
mitochondrial membranes, it may represent a potential area for crosstalk between 
sphingolipids and ICl,swell.  Use of mitoPMP blockers such as bongkrekic acid or 
cyclosporin A would help to identify this as a mechanism for modulation SMase-induced 
ICl,swell activation.  Additionally, SMase-D could be used to deplete the membrane of 
sphingomyelin and exogenous ceramide or sphingosine could be added in the perfusate.  
If mitoPMP induction and ROS release is due to ceramide or sphingosine channel 
formation, a bongkrekic acid-sensitive activation of ICl,swell would be observed under 
these conditions. 
Lipid-protein interactions are significant determinants of protein function.  There 
are two principle methods for lipids and proteins to interact: through direct, species-
specific interactions and through indirect, membrane property alterations (Andersen and 
Koeppe, 2007).  As sphingolipids play an important role in the structural properties of 
membranes, the potential for SMase-induced ICl,swell to be mediated through membrane 
alterations exists.  Sphingolipids, along with cholesterol, are the primary components of 
the localized membrane domains known as lipid rafts.  They are also found in high 
concentrations in the U-shaped membrane invaginations called caveolae (Dobrowsky, 
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2000).  Lipid rafts and caveolae have been implicated as key participants in signaling and 
ion channel regulation.  Detergents such as Triton X-100 and methyl-beta cyclodextrin, a 
cholesterol ligand, disrupt lipid rafts and caveolae and thus are useful tools for studying 
their importance in signaling and ion channel function.  Use of such detergents in our 
system would allow the role of these lipid platforms in SMase-induced activation of 
ICl,swell.  It is also possible that the generation of H2O2 near the sarcolemmal membrane is 
leading to peroxidation of membrane lipids.  This may lead to modification of the 
membrane properties and thus perturbation of channel function.  As the channel identity 
is unknown, this is one potential way ROS is mediating ICl,swell.   
 
 As alluded to previously, investigation of the role of S1P receptors and potentially 
differential effects of sphingolipids of different chain lengths in this system is worth 
exploration.  There is evidence that the length of ceramide acyl chains is a determinant of 
the differential effect of ceramide on signaling and membrane properties (Wijesinghe et 
al., 2005; Tang et al., 2007; Sot et al., 2005).  Quantifying the absolute and relative 
changes in sphingolipid metabolism due to stimuli such as osmotic swelling using tandem 
mass spectrometry may help illuminate the role of various ceramide sub-species.  The 
differential expression and activity of S1P receptors contributes an additional layer of 
complexity and specificity for sphingolipid signaling.  Specific inhibitors of SPHK1 and 
certain S1P receptors have been developed.  While this pharmacopeia is incomplete, it 
does provide tools that may allow us to probe the role of S1P receptors and localized S1P 
production in SMse-induced ROS production and ICl,swell activation. 
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 ICl,swell plays an obvious role in volume regulation, however the volume-sensing 
mechanism is not well understood.  We have previously shown that ROS are downstream 
of the volume-sensing mechanism as ICl,swell elicited by H2O2 is insensitive to 
hyperosmotic cell shrinkage (Ren et al., 2008).  ICl,swell may more accurately be described 
as a stress sensor, responding to H2O2 induced by a number of different stress stimuli.  As 
ceramide and S1P both elicit ICl,swell through ROS generation, cell fate may be determined 
by the total amount of ROS present.  Below a certain threshold, ROS induce stress 
response mechanisms, including ICl,swell, that attempt to compensate for the perturbation.  
Above this threshold, the stress response mechanisms may become overwhelmed and 
begin the apoptotic process.  This potentially explains the similar effects of S1P and 
ceramide in ICl,swell activation in cardiomyocytes.  As demonstrated in this study, both 
induce ROS but the relative concentrations produced may differ significantly.  This could 
be addressed by using quantitative methods to determine the amounts of ROS produced 
by each sphingolipid species.  Additionally, ROS generation may be localized to different 
compartments for the different species.  Techniques such as confocal microscopy may be 
useful in addressing this question.  The observation that sphingolipids and ROS are both 
involved in cardiac preconditioning in ischemia/reperfusion injury lends support to the 
hypothesis that lower concentrations of ROS may have beneficial effects by “priming” 
the stress response machinery for cell survival.  Determination of the dose response 
relationship of ICl,swell would be an important step in testing this hypothesis. 
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